Skip to main content
eLife logoLink to eLife
. 2019 Jun 24;8:e44698. doi: 10.7554/eLife.44698

Monitoring site-specific conformational changes in real-time reveals a misfolding mechanism of the prion protein

Ishita Sengupta 1,†,, Jayant Udgaonkar 1,‡,
Editors: Andreas Martin2, John Kuriyan3
PMCID: PMC6590988  PMID: 31232689

Abstract

During pathological aggregation, proteins undergo remarkable conformational re-arrangements to anomalously assemble into a heterogeneous collection of misfolded multimers, ranging from soluble oligomers to insoluble amyloid fibrils. Inspired by fluorescence resonance energy transfer (FRET) measurements of protein folding, an experimental strategy to study site-specific misfolding kinetics during aggregation, by effectively suppressing contributions from inter-molecular FRET, is described. Specifically, the kinetics of conformational changes across different secondary and tertiary structural segments of the mouse prion protein (moPrP) were monitored independently, after the monomeric units transformed into large oligomers OL, which subsequently disaggregated reversibly into small oligomers OS at pH 4. The sequence segments spanning helices α2 and α3 underwent a compaction during the formation of OL and elongation into β-sheets during the formation of OS. The β1-α1-β2 and α2-α3 subdomains were separated, and the helix α1 was unfolded to varying extents in both OL and OS.

Research organism: E. coli

Introduction

The structural characterization of kinetic intermediates in protein aggregation is a challenging task. Most experimental probes, used to study misfolding and aggregation kinetics, track either the acquisition of β-structure, or global changes in size. Although intermediate forms populated transiently during fibril formation reactions can be detected, for example by single-molecule FRET measurements (Cremades et al., 2012; Orte et al., 2008; Shammas et al., 2015; Yang et al., 2018), their detailed structural characterization is difficult. Equilibrium and kinetic measurements using multi-site FRET, to probe conformational changes in different parts of a protein, while it folds, unfolds, forms functional oligomers or interacts with its binding partner, have been a rich source of site-specific information, usually invisible to global probes (Lakshmikanth et al., 2001; Lillo et al., 1997; Lin et al., 2013). Using a similar approach to study misfolding can potentially reveal the step-wise conformational changes that lead to the global misfolding of a protein.

The mostly α-helical and monomeric prion protein (PrP) undergoes drastic secondary and tertiary structural re-arrangements upon aggregation into a variety of misfolded β-sheet-rich multimers (Pan et al., 1993), most of which are not infectious. A class of fatal neurodegenerative diseases collectively known as transmissible spongiform encephalopathies are caused by infectious aggregates of misfolded PrP. Conversion to the pathogenic form possibly initiates in the endocytic pathway, when the protein encounters an acidic environment (Borchelt et al., 1992). The pathogenic misfolded aggregates thus formed in vivo are highly heterogeneous, with the most infectious oligomers composed of 14–28 monomers (Silveira et al., 2005).

The extremely rugged aggregation landscape of PrP has made it challenging to determine the high-resolution structure(s) of its various misfolded β-rich aggregated forms. However, several structural models have been derived from experimental data, which differ not only in their secondary structure content, but also in the location and size of the β-sheet-rich core. While some models suggest that a major part of the native fold remains intact in the aggregates (DeMarco and Daggett, 2004; Govaerts et al., 2004), several experimental studies have shown that a major section of the β-rich core of the aggregates formed from the full length PrP is located in the sequence segment that corresponds to the α2-α3 subdomain of monomeric PrP (Cobb et al., 2007; Diaz-Espinoza and Soto, 2012; Singh et al., 2012Tycko et al., 2010). It has been a challenge to determine the mechanism of misfolding that occurs during the formation of any of the distinct β-rich aggregates of PrP.

In agreement with observations made in vivo, the oligomerization and misfolding of mouse PrP (moPrP) is favoured in vitro at low pH in the presence of 150 mM NaCl (Singh et al., 2014; Singh and Udgaonkar, 2015b), due to the protonation of residues H186 and/or D201 in the α2-α3 subdomain of moPrP. Previous HX-MS studies (Singh et al., 2012; Singh and Udgaonkar, 2015a) had shown that the protected core region of the β-rich oligomers formed by PrP at low pH in vitro resembles that of amyloid fibrils derived from diseased brain. Not surprisingly then, recombinant PrP from animal species with high susceptibility to prion disease has been shown to readily form β-rich oligomers at low pH in vitro (Khan et al., 2010). β-rich oligomers formed at low pH, readily disrupt lipid membranes; this property is a likely reason for their toxicity (Singh et al., 2014; Singh et al., 2012). Thus, the β-rich oligomers formed at low pH appear to be a suitable structural model for studying a putatively important misfolding mechanism of PrP.

Interestingly, oligomer formation of moPrP at pH 4 could be completely abolished by substituting a discordant but highly conserved sequence stretch (TVTTTT) in the C-terminal end of α2, with a very high β-sheet propensity (Dima and Thirumalai, 2002), by the α-helix favouring residue alanine (AAAAAA) (Singh et al., 2014). This suggests that the C-terminal end of α2 plays a critical role in the initiation of misfolding. In species with low susceptibility to prion disease, the loop between β2 and α2 is more rigid in the monomeric prion protein (Gossert et al., 2005), suggesting that its flexibility might play an important role in facilitating misfolding. It is also known that residues H186 and D201 together with R155, K193 and E195 form a network of electrostatic interactions between the α2-α3 and β1-α1-β2 subdomains in monomeric PrP (Hadži et al., 2015; Hosszu et al., 2010; Singh and Udgaonkar, 2015b). The disruption of these electrostatic interactions either by a lowering of pH (Singh and Udgaonkar, 2016a) and addition of salt (Sengupta et al., 2017), or by charge reversing or neutralizing pathogenic mutations (Singh and Udgaonkar, 2016a; Singh and Udgaonkar, 2015a) facilitate misfolding and oligomer formation in vitro. It appears that separation of the α2-α3 and β1-α1-β2 subdomains must occur before conversion to the β-conformation (Eghiaian et al., 2007; Hafner-Bratkovic et al., 2011). Locking of the α2-α3 and β1-α1-β2 subdomains either by engineering in an artificial disulphide bond (Eghiaian et al., 2007), or by binding to anti-prion drugs (Kamatari et al., 2013) prevent misfolding and aggregation. While such equilibrium studies have suggested possible sequences of structural changes during oligomer formation (Singh and Udgaonkar, 2016a), there has been a dire need for kinetic studies that can directly delineate the structural mechanism of the misfolding which accompanies the oligomerization of the prion protein at low pH.

In the current study, the structural mechanism of the spontaneous formation of β-rich oligomers at pH 4, in the absence of any denaturant but in the presence of 150 mM NaCl, has been delineated. Earlier studies of the formation of these misfolded oligomers had indicated that oligomerization drives major intra-molecular conformational change. Real-time NMR measurements had shown that no major conformational change occurs in the monomer before it assembles into oligomer: the monomer structure is perturbed to only a very minor extent before assembly into oligomers, which is rate-limited by association steps in which dimers and trimers are formed (Sengupta et al., 2017). Not surprisingly, single-molecule studies have found that misfolded monomeric PrP is not stable (Yu et al., 2012). Measurements of changes in size and conformation by CD (circular dichroism), SEC (size-exclusion chromatography) and HX-MS (hydrogen-exchange coupled to mass spectrometry), had shown that oligomerization is faster than major conformational change in the case of two pathogenic mutant variants of moPrP (Sabareesan and Udgaonkar, 2016), under oligomerization conditions identical to those used in the current study. Notably, β-rich oligomers of moPrP, which form worm-like fibrils by an isodesmic mechanism at pH 2 (Jain and Udgaonkar, 2008), are distinct from the off-pathway oligomers seen to form transiently during nucleation-dependent amyloid fibril formation (Sabareesan and Udgaonkar, 2017), from the octamers formed at low pH in the presence of 2 M urea (Larda et al., 2013), from the oligomers formed spontaneously by a tandem dimer (Gilch et al., 2003), and from the neurotoxic oligomers obtained by thermal refolding of ovine prion protein (Eghiaian et al., 2007; Rezaei et al., 2005).

Most kinetic studies of protein misfolding have lacked sufficient structural resolution or have been complicated by the effects of multimerization. Deriving inspiration from site-directed spin labelling (SDSL) EPR and FRET measurements on protein aggregates (Margittai and Langen, 2008) and very successful kinetic studies of protein folding, using multi-site FRET (Lakshmikanth et al., 2001; Lillo et al., 1997) a generally applicable method was developed to measure site-specific misfolding kinetics in non-nucleated aggregating systems, while eliminating the complicating effects of multimerization. This was achieved using FRET between a Trp residue and a thio-nitrobenzoate (TNB)-moiety attached to a free Cys residue (Lakshmikanth et al., 2001), in five different single Trp, single Cys-containing mutant variants of moPrP. Every pair of proteins, with and without the TNB adduct, was separately co-oligomerized with a large excess of a tryptophan-free (Trp-less) mutant variant of moPrP. Such an experimental strategy has been shown to result in the suppression of inter-molecular contributions to FRET (Duim et al., 2014; Pinotsi et al., 2014); hence, the FRET measurements report only on structural changes occurring in each monomeric unit comprising the oligomer.

To complement the FRET studies, which were used to monitor conformational changes within each monomeric unit of the oligomer, techniques that monitored changes in the global properties of the oligomers were employed. CD was used to monitor global changes in secondary structure (mostly β-sheet formation), and steady-state tryptophan fluorescence intensity and anisotropy were used to measure changes in the local environments of differently placed Trp residues, and in overall oligomer size/population, respectively. Size-exclusion chromatography was used to monitor the kinetics of monomer loss during oligomer formation, and to characterize the heterogeneity in the oligomer formation. It should be noted that by themselves probes such as CD, cannot detect site-specific structural changes, because the signal is dominated by β-sheet formation, making it insensitive to any other conformational change. In contrast, the experimental strategy demonstrated here, allows the visualization of segment-specific misfolding of moPrP, during the course of oligomer formation at low pH. It is, however, not possible to distinguish whether all monomeric units undergo these conformational changes synchronously or in a random manner, using this approach.

Taken all together, the fluorescence and FRET data revealed that a local perturbation in the loop separating α2 and α3 took place prior to oligomer formation. Along the course of the oligomerization reaction, the fastest change appeared to be the compaction of the sequence segments spanning helices α2 and α3. The separation of the α2-α3 sub-domain from the β1-α1-β2 subdomain appeared to be slower. The slowest changes appeared to be the unfolding of α1, and the expansion of the sequence segments that encompassed α2 and α3 into extended β-strands. From the size-exclusion chromatography results, two oligomeric species of distinct sizes, OL and OS, were seen to be populated to varying extents at all times of the oligomerization reaction, suggesting that monomer M, OL and OS were interconverting. Kinetic modelling and global fitting of the conversion of M to OL and OS, revealed that the contraction of the sequence segments spanning helices α2 and α3 took place concomitant to the formation of oligomer OL from monomers, and their expansion took place as OL disaggregated reversibly to form OS. α1 was unfolded and the α2-α3 sub-domain was separated from the β1-α1-β2 subdomain to varying extents in both OL and OS.

Results

FRET pairs to monitor site-specific misfolding in the monomeric unit of the oligomer

The Trp-TNB FRET pair has an estimated Forster radius (R0) of ~23 Å (Supplementary file 1), which allows the reliable measurement of change in distance in the range of ~11 to ~35 Å (Lakshmikanth et al., 2001). WT moPrP has eight Trp residues, seven of which are located in the intrinsically disordered N terminal region (NTR), and one (W144) at the N terminus of α1 in the structured C-terminal domain (CTD). All native Trp residues are solvent-exposed in the WT moPrP monomer. The NTR remains disordered in the oligomer, and major structural changes take place in the CTD upon oligomerization (Sengupta et al., 2017; Singh and Udgaonkar, 2015a). To monitor these changes, five single Trp, single Cys-containing mutant variants in the CTD were designed for site-specific FRET measurements: W144-C153 to monitor conformational changes in α1; W144-C199 and W144-C223 to monitor the separation of α1 from the α2-α3 subdomain; and W197-C169 and W197-C223 to monitor conformational changes within α2 and α3 (Figure 1A).

Figure 1. FRET in mutant variants of moPrP in their monomeric and oligomeric forms.

(A) Structure of moPrP (PDB ID 1AG2) showing the positions of the FRET pairs. The donor tryptophans, W144 and W197 are shown as blue sticks, and the acceptor cysteines with covalently bound TNB moieties are shown as orange spheres. The five single Trp, single Cys-containing mutant variants, corresponding to W144-C153, W144-C199, W144-C223, W197-C169 and W197-C223 are shown. The secondary structural elements, N and C-termini and disulphide bond are indicated. (B-F) Fluorescence emission spectra of unlabelled (blue) and TNB-labelled (orange) the single Trp, single Cys-containing mutant variants in their monomeric (solid lines) and oligomeric forms (dashed lines) are shown. The relevant FRET pairs are indicated in each panel.

Figure 1.

Figure 1—figure supplement 1. ESI-MS spectra of all unlabelled and labelled mutant variants.

Figure 1—figure supplement 1.

All proteins have the native disulfide bond between residues C178 and C213 intact. All proteins (except W197-C223-DANS) are >95% labelled, with one adduct per molecule.
Figure 1—figure supplement 2. Thermodynamic stability and far-UV CD monitored misfolding kinetics of Trp-less and labelled and unlabelled single Trp, single Cys-containing mutant variants of moPrP.

Figure 1—figure supplement 2.

(A) Far-UV CD spectra of monomeric (solid line) and oligomeric (dashed line) of WT, Trp-less, unlabelled, TNB and DANS-labelled single Trp, single Cys-containing mutant variants of moPrP. The secondary structure for all mutant variants in both the monomeric and oligomeric forms are comparable to that of WT moPrP. (B) Urea-induced equilibrium unfolding transitions of WT, Trp-less, unlabelled, TNB and DANS-labelled single Trp, single Cys-containing mutant variants of moPrP at pH 4, 25°C as monitored by far-UV CD at 222 nm. (C) DLS measurements of WT and Trp-less moPrP oligomers formed at pH 4 in the presence of 150 mM NaCl. The Rh of the oligomers were ~11 and~13 nm for Trp-less and WT moPrP, respectively. (D) Misfolding of 100 µM single Trp, single Cys-containing mutant variants of moPrP at pH 4 in the presence of 150 mM NaCl as monitored by measuring the far-UV CD signal at 228 nm. The Trp-less mutant variant misfolds slower than all other variants. All unlabelled single Trp, single Cys-containing mutant variants, with the exception of W197-C169 oligomerize with rate constants comparable to that of WT moPrP. All TNB-labelled proteins, other than W144-C153-TNB, misfolds 4–5 fold faster than their unlabelled counterparts. W197-C169-DANS and W197-C223-DANS misfold 2–3 fold faster than their TNB-labelled counterparts.

The donor fluorophore was W144 at the N terminus of α1 in three of the five mutant variants, and W197, in the loop between α2 and α3 in the other two variants (Jenkins et al., 2008). The native disulphide bond between residues C178 and C213 was intact in all of the constructs as judged by ESI-MS mass spectrometry (Figure 1—figure supplement 1). The extra Cys residue in each of the mutant variants was covalently modified with TNB (thionitrobenzoate), DNP-C2 (dinitrophenyl) (Yu et al., 2012) or DANS (5-(DimethylAmino)Naphthalene-1-Sulfonyl) to obtain the corresponding labelled protein(s). It is to be noted that it has been shown previously by HX-MS/NMR measurements, that α1 (which houses the buried C153 residue) is much more flexible than the hydrophobic core of the protein which houses the disulfide bond. In fact, residues in the hydrophobic core do not exchange even after 40 days under these conditions (Moulick et al., 2015). Therefore, while the fast dynamics of α1 allow the buried C153 side-chain to get labelled, the disulfide bond between residues C178 and C213 remains oxidized in that timescale. A Trp-less mutant variant, with all Trp residues mutated to Phe residues was also purified for co-oligomerization experiments, in which it could be shown that inter-molecular FRET was suppressed during oligomerization.

Fluorescence and FRET efficiency changes in monomeric and oligomeric moPrP

Prior to the kinetic experiments, fluorescence emission spectra were recorded for each pair of unlabelled and TNB-labelled proteins, in their monomeric and oligomeric forms. The fluorescence emission maximum was at 355 nm and 345 nm, for monomeric mutant variants with W144 and W197 as the donor fluorophore, respectively (Figure 1B–F). This observation, indicating a markedly different local environment around each Trp residue, is in agreement with the solution NMR structure of monomeric moPrP, where W144 is completely exposed to solvent, and W197 is partially buried (Riek et al., 1996). In the corresponding TNB-labelled monomeric mutant variants, the Trp fluorescence was quenched, but to different extents. The extent of quenching by TNB was dependent on the separation of the Trp and the TNB moiety in the monomer, clearly indicative of FRET. In addition, the observed FRET efficiencies for different pairs of mutant variants were in good agreement with the expected FRET efficiencies calculated from the solution NMR structure (Figure 1A). The small differences in the expected and observed FRET efficiencies can be attributed to the size and orientation of the Trp and TNB-side chains (Supplementary file 1). Moreover, the far-UV CD spectra of all unlabelled and TNB-labelled mutant variants matched well with that of WT moPrP (Figure 1—figure supplement 2), indicating that the secondary structure is conserved in these proteins.

While all the unlabelled and TNB-labelled mutant variants were able to form β-rich oligomers, comparable to those formed by WT moPrP as judged by CD and DLS measurements (Sengupta and Udgaonkar, 2017), (Figure 1—figure supplement 2), the local environment around donor fluorophores W144 and W197 changed in different ways upon oligomer formation. A blue shift to 345 nm and an increase in quantum yield was observed for the W144-containing mutant variants, suggesting that the local environment of W144 was more hydrophobic in the oligomers than in the monomer (Figure 1D–F). In contrast, a slightly decreased quantum yield without a change in the emission maximum was observed for the W197-containing mutant variants (Figure 1B–C) indicating that the W197 side-chain was partially buried in both monomer and oligomer, but that additional quenching mechanisms were operative in the oligomer. The W197 side-chain in the monomer is in close proximity to residues H186 and Y155, which like the disulfide bond, can quench Trp fluorescence, either by excited state proton and electron transfer, or by direct contact, respectively (Hennecke et al., 1997; Lakowicz, 2006). Rearrangements in structure in each monomeric unit of the oligomer, or between monomeric units within the oligomer, can result in quenching, due to the proximity of these residues to W197. The enhanced FRET efficiency in the oligomers compared to the monomers, in all five mutant variants, suggested that both intra- and inter-molecular FRET could be contributing to the quenching of the tryptophan fluorescence in the oligomers.

Co-oligomerization with Trp-less moPrP results in the suppression of inter-molecular FRET

To suppress the inter-molecular contribution to FRET in the oligomers, and to exclusively measure intra-molecular FRET changes during oligomer formation, single Trp-containing labelled and unlabelled protein (dopant) were co-oligomerized with increasing amounts of Trp-less moPrP (while keeping the total protein concentration fixed at 100 µM) (Toyama and Weissman, 2011).

The FRET efficiencies were similar for the oligomers prepared at 1:34 (~3 mol%) and 1:50 (2 mol%) doping ratios (Figure 2A), and significantly lower than that determined for oligomers prepared from the dopant protein alone (i.e. without Trp-less moPrP), or for oligomers prepared at a 1:13 (~8 mol%) doping ratio. The data suggested that at doping ratios greater than ~1:30, inter-molecular FRET was effectively suppressed.

Figure 2. Co-oligomerization with Trp-less moPrP suppresses inter-molecular FRET but does not alter the global misfolding kinetics significantly.

Figure 2.

(A) Co-oligomerization with Trp-less moPrP suppresses inter-molecular FRET between monomers. Oligomers prepared from solely (100%) unlabelled and TNB-labelled W144-C153 moPrP (dopant) exhibit the highest FRET efficiency (red). To effectively suppress inter-molecular FRET between monomers that is units in the oligomer, oligomers were prepared in the presence of increasing concentrations of Trp-less moPrP, resulting in decreasing dopant concentrations of 8 (orange), 3 (bright yellow) and 2 mol% (pale yellow), while keeping the total protein concentration fixed at 100 µM. The FRET efficiencies were comparable in the oligomers prepared from 3 and 2 mol% dopant concentrations, respectively, and significantly lower than that in the oligomers prepared from 100% dopant concentration. (B) Global misfolding kinetics of Trp-less moPrP, W197-C223-TNB and Trp-less moPrP doped with 1, 2, 10 and 20 mol% of W197-C223-TNB moPrP (dopant). Far-UV CD was the probe. The dopant by itself (orange) misfolds ~ 10 fold faster than Trp-less moPrP. The total protein concentration in each sample was 100 µM. Solid orange and gray lines represent the fit of the global misfolding data to single exponential kinetics for W197-C223-TNB and the Trp-less proteins, respectively. The misfolding rate constants are only marginally affected upon doping with increasing concentrations of the fast misfolding dopant. Error bars are standard deviation of the mean, determined from three independent measurements, from three separate samples. (C) Co-oligomerization of Trp-less moPrP with 2 mol% of W144-C153-TNB and W197-C223-TNB monitored by tryptophan steady-state fluorescence anisotropy.

Figure 2—source data 1. Raw data for Figure 2A–C.
DOI: 10.7554/eLife.44698.006

The moPrP oligomers formed at pH 4 are comparable to the β-sheet rich oligomers at pH 2 (Jain and Udgaonkar, 2008) (Jain and Udgaonkar, 2010) (Jain and Udgaonkar, 2011), with a molecular weight of 1207 ± 165 kDa from MALS measurements (Singh et al., 2012), corresponding to ~53 ± 7 monomeric units. Thus, a 1:50 doping ratio would correspond to one dopant molecule in every ~50 mer (oligomer), on the average. It was therefore not surprising that intermolecular-FRET was effectively supressed at a 1:50 doping ratio.

Unlabelled and TNB-labelled mutant variants form misfolded co-oligomers with Trp-less moPrP with comparable kinetics

An important pre-requisite for using FRET to monitor the kinetics of intra-molecular conformational change during oligomerization was that the different unlabelled and TNB-labelled mutant variants must co-oligomerize with Trp-less moPrP to form misfolded co-oligomers, with comparable rate constants. In order to verify that the fast misfolding kinetics of the dopant protein by itself had no influence on how fast it formed misfolded co-oligomers with Trp-less moPrP, the global misfolding kinetics of doped Trp-less moPrP was monitored by far-UV CD at four doping ratios (1:5, 1:10, 1:50 and 1:99) corresponding to 20, 10, 2 and 1 mol% of TNB-labelled W197-C223 moPrP (dopant) (Figure 2B). TNB-labelled W197-C223 moPrP was chosen as the dopant as it misfolds nearly 10-fold faster by itself at 100% labelling density, compared to Trp-less moPrP (Supplementary file 2). The global misfolding kinetics at 1:50 and 1:99 doping ratios were indistinguishable from that of only Trp-less moPrP. Only slightly faster kinetics was observed at 1:5 and 1:10 doping ratios (Supplementary file 3). It should be noted that although the observed kinetics appear to be described well by a single exponential equation, it is not possible to rule out the presence of two exponential components, with one component too small in amplitude to be detected.

The observations that at a 1:50 doping ratio, inter-molecular FRET was effectively suppressed in oligomers, and the CD-monitored kinetics of misfolding of Trp-less moPrP was unaffected, suggested that the use of this doping ratio was appropriate for monitoring the kinetics of intra-molecular FRET change during oligomerization.

To conclusively demonstrate that at a doping ratio of 1:50, the dopant protein and Trp-less moPrP did not oligomerize independently of each other, or that the oligomerization kinetics of Trp-less moPrP was altered, 2 μM dopant protein was mixed with 98 μM Trp-less protein, and the oligomerization reaction was monitored by steady-state Trp fluorescence anisotropy (Figure 2C and Supplementary file 4). This probe monitors the increase in size/population of oligomers that contain dopant protein (which contains the Trp fluorophore) and does not report on oligomers containing only Trp-less moPrP. Two dopant proteins, TNB-labelled W197-C223 and TNB-labelled W144-C153 were used at the 1:50 doping ratio. Although 100 μM TNB-labelled W197-C223 by itself misfolded more than fourfold faster than 100 μM TNB labelled W144-C153 (Supplementary file 2), the kinetics measured by steady-state fluorescence anisotropy was the same, no matter which of them was used as dopant at the 1:50 doping ratio. Moreover, the kinetics was comparable to the kinetics of CD-monitored misfolding of 100 μM Trp-less moPrP by itself. Taking the steady state fluorescence anisotropy measurements into consideration, it was not surprising to find that the CD-monitored misfolding kinetics of Trp-less moPrP doped with the different unlabelled and TNB-labelled mutant variants were similar (Figure 3A) at the 1:50 doping ratio. Furthermore, at 2 μM concentration, either dopant protein by itself is expected to oligomerize with an apparent rate constant of <0.02 h−1, from the known dependence of the oligomerization rate of moPrP on protein concentration (Sabareesan and Udgaonkar, 2016). The observation that the apparent rate constant from steady state Trp fluorescence anisotropy measurement was 0.1 h−1, indicated that this probe reported on the co-oligomerization of dopant protein and Trp-less moPrp, and not on the independent oligomerization of 2 μM dopant protein.

Figure 3. Global misfolding and oligomerization kinetics of Trp-less moPrP doped with 2 mol% of the unlabelled and TNB-labelled single Trp, single Cys-containing mutant variants of moPrP, monitored by CD and size-exclusion chromatography, respectively.

(A) None of the dopant proteins altered the global misfolding kinetics of Trp-less moPrP to a significant extent at the dopant concentrations used in these experiments. The total protein concentration was kept fixed at 100 µM in all experiments. Global misfolding was monitored using far-UV CD. Error bars are standard deviation of the mean, determined from three independent measurements, from three separate samples. The global misfolding rate, as determined from a single exponential fit of all the data was 0.09 ± 0.03 h−1. (B) Size-exclusion chromatograms at different time points of oligomerization of 100 µM Trp-less moPrP, showing the presence of oligomers OL, OS and monomer M. (C) Normalized monomer loss kinetics, estimated from (B). The black line through the data is shown as a guide to the eye.

Figure 3—source data 1. Raw data for Figure 3.
DOI: 10.7554/eLife.44698.009

Figure 3.

Figure 3—figure supplement 1. Trp-less moPrP shows a negligible change in fluorescence intensity upon oligomerization.

Figure 3—figure supplement 1.

Oligomerization of 98 µM of Trp-less moPrP shows no change in fluorescence signal over a period of 12 hr. This indicated that the contribution of scatter to the fluorescence signal at this wavelength (340 nm) was negligible. The average fluorescence signal was subtracted from all experiments to account for the background signal of 98 µM Trp-less moPrP, present in all samples, for suppression of inter-molecular FRET. Similar background correction was also made for samples containing dopant at a 1:99 doping ratio. Error bars are standard deviation of the mean, determined from three independent measurements.

The fluorescence spectra of the native monomers of the different unlabelled and labelled moPrP variants differed from those of the corresponding misfolded oligomers (Figure 1). Since there was no measurable change in fluorescence accompanying the misfolding and oligomerization of Trp-less moPrP by itself (Figure 3—figure supplement 1), the fluorescence change accompanying co-oligomerization of 2 μM dopant protein with 98 μM Trp-less moPrP, was easily measurable. Importantly, it was only when 2 µM dopant protein (any one of the unlabelled and TNB-labelled mutant variants) was mixed with 98 µM Trp-less moPrP, under oligomerization conditions, that a change in Trp fluorescence intensity was observed (Figure 4). 2 µM dopant protein alone (in the absence of Trp-less moPrP) under oligomerization conditions did not undergo any conformation-sensitive change in Trp fluorescence in ~30 hrs (Figure 4). These results also suggested that in the presence of 98 µM Trp-less moPrP, it was very unlikely that 2 µM dopant protein could misfold before oligomerization, and supported the results of the steady state Trp fluorescence anisotropy measurements which had indicated that the two proteins co-oligomerized.

Figure 4. Monitoring misfolding by site-specific intra-molecular FRET.

Unlabelled (blue) and TNB-labelled (orange) single Trp, single Cys-containing mutant variants W144-C153, W144-C199, W144-C223, W197-C169 and W197-C223 (A–E) were either co-oligomerized separately with Trp-less moPrP at a dopant concentration of 2 mol% (filled symbols), or in its absence (empty symbols). The corresponding changes in tryptophan fluorescence emission were measured as a function of time. The tryptophan fluorescence signal for the monomeric unlabelled (blue) and TNB-labelled (orange) protein(s) are shown as solid lines, and the corresponding signals for the oligomeric protein(s) are shown as dashed lines. From both sets of data, the kinetics of FRET efficiency change for all five FRET pairs (F–J) was calculated (filled and empty green circles).The black lines through the data are a guide to the eye. The error bars in the fluorescence measurements are standard deviation of the mean, determined from four to five independent measurements, on separate samples. The error bars in the FRET efficiency were determined by propagating the errors in the fluorescence measurements.

Figure 4—source data 1. Raw data for Figure 4A–J.
DOI: 10.7554/eLife.44698.016

Figure 4.

Figure 4—figure supplement 1. Concentration dependence of co-oligomerization monitored by fluorescence intensity.

Figure 4—figure supplement 1.

(A) Co-oligomerization of 49, 98 and 196 µM Trp-less moPrP doped with 1, 2 and 4 µM of unlabelled W197-C223 moPrP, monitored by tryptophan fluorescence, such that the total protein concentration is 50, 100 and 200 µM, respectively, with a fixed dopant concentration of 2 mol%. In the absence of co-oligomerization, the signal remains fixed at 1, indicating the absence of photobleaching in these timescales. The characteristic times for the fluorescence changes for the three cases are ~33 hr, ~8 hr and ~3 hr, respectively. (B) The dependence of log (ν0/C0) (concentration normalized initial rate obtained from the linear regression of the initial 4–5 data points in (A) on log (C0). The slope, n-1 is 1.68, which matches very well with the value of 1.6, obtained previously from NMR measurements (Sengupta et al., 2017).
Figure 4—figure supplement 2. Effect of doping ratio on fluorescence-monitored kinetics of co-oligomerization.

Figure 4—figure supplement 2.

Unlabelled (A) W197-C223 moPrP and (B) W144-C153 moPrP were co-oligomerized with Trp-less moPrP at a 1:99 doping ratio, while keeping total protein concentration fixed at 100 µM. Black solid lines are shown as a guide to the eye. The characteristic times for (A) and (B) were estimated to be ~10–11 hr.
Figure 4—figure supplement 3. FRET monitored site-specific misfolding kinetics with W197-C223-DNP, W197-C169-DANS and W197-C223-DANS.

Figure 4—figure supplement 3.

Unlabelled (blue) and labelled (red) DNP-C2 (A) or DANS-labelled (D and F) single Trp, single Cys-containing mutant variants of W197-C223 and W197-C169 (dopant) were co-oligomerized with Trp-less moPrP, at a dopant concentration of 2 mol%. The corresponding changes in tryptophan fluorescence emission were measured as a function of time. (B) DNP-C2-labelled W197-C223 moPrP (marked in black box in (A)), (D) W197-C169-DANS and (F) W197-C223-DANS also showed faster kinetics, similar to W197-C223-TNB (C) FRET-monitored misfolding kinetics for W197-C223 using the Trp-DNP FRET pair. (E) and (G) Same as (C) except the proteins were W197-C169-DANS and W197-C223-DANS, respectively. Black solid lines are shown as a guide to the eye. The characteristic times for (C), (E) and (G) were estimated to be 1.7 and 14.3 hr, 1.9 and 8.3 hr, 1.9 and 10.0 hr, respectively.
Figure 4—figure supplement 4. Time-resolved fluorescence anisotropy measurements to estimate κ2.

Figure 4—figure supplement 4.

For W197-containing mutant variants in both monomeric and oligomeric forms, two rotational correlation times were observed for both donor tryptophan and acceptor 1,5-IAEDANS (Supplementary file 5). The black dashed lines correspond to the measured fundamental anisotropies of 0.4 and 0.36, respectively, for donor tryptophan and acceptor 1,5-IAEDANS determined from time-resolved anisotropy measurements of free dyes NATA (N-Acetyl-L-tryptophanamide) and 1,5-IAEDANS in 70% glycerol. The significant amplitudes of the fast components suggest that both donor and acceptor are freely rotating and a κ2 = 2/3 can be assumed (See Appendix 1 and Supplementary file 5).
Figure 4—figure supplement 5. Correlation analysis of global misfolding rates with thermodynamic stability and intrinsic physico-chemical properties, and measurement of local stability by FRET ratio and co-oligomerization kinetics by steady-state anisotropy.

Figure 4—figure supplement 5.

No significant correlation was found between the global misfolding rate constant of the mutant variants with change in thermodynamic stability (A), change in hydrophobicity (B) and change in β-sheet propensity (C). The local stabilities monitored by FRET ratio for W197-C169-DANS (D) and W197-C223-DANS (E) mutant variants were comparable to those obtained from HX-MS and HX-NMR measurements of WT moPrP (see Appendix 1).

Thus, when the dopant was present at 2 mol%, the kinetics of conformational change was not dependent on whether the dopant was labelled with TNB or not. Hence, the fluorescence-monitored kinetics of 2 mol% of the different unlabelled and TNB-labelled proteins could be compared directly in subsequent FRET measurements of site-specific misfolding.

Oligomer formation monitored by size-exclusion chromatography

To directly monitor the change in population and/or size of the oligomers, size-exclusion chromatography (SEC) was carried out. In agreement with previous results obtained with WT moPrP (Singh et al., 2014), Trp-less moPrP was found to form two populations of oligomers, the larger OL and the smaller OS, at pH 4 and 150 mM NaCl, As oligomerization progressed, the total amount of oligomers increased, but the sizes (as estimated from their elution volumes) remained fixed (Figure 3B). The kinetics of monomer loss/oligomer formation, as determined from the SEC measurements, were found to be apparently single exponential in nature, with a characteristic time (1/k) of 16.7 ± 2.8 hr (Figure 3C). Due to the limited resolution of the SEC column, it was not possible to separate the two oligomers and experimentally determine their FRET efficiencies. The populations of M and of OL and OS together were estimated to be ~14% and ~86%, respectively, after 60 hr of oligomerization. The poor resolution of the SEC column made it difficult to reliably estimate the relative amounts of OL and OS at equilibrium, but it appeared that, OS was populated to about a threefold higher extent than was OL.

Local conformational change in moPrP monitored by fluorescence change

Changes in Trp fluorescence intensity can detect local conformational changes during co-oligomerization. Here, the co-oligomerization of the three unlabelled mutant variants containing W144 (W144-C153, W144-C199 and W144-C223) with Trp-less moPrP was accompanied by a slow ~80% increase in fluorescence in a single kinetic phase with characteristic times (1/k) of 8.3 ± 1.3, 6.7 ± 2.7 and 10 ± 1 hr, respectively (Figure 4A–C and Table 1). The amplitude of the signal change as well as the misfolding kinetics for all three unlabelled proteins was comparable. In marked contrast to the W144 variants, the two unlabelled mutant moPrP variants containing W197 (W197-C169 and W197-C223) underwent a quenching of fluorescence in two kinetic phases: a burst phase change (~40% amplitude) which was complete within the dead time of measurement (5 min), and a slow phase which accounted for the rest of the signal change (~60% amplitude) during the co-oligomerization reaction (Figure 4D–E). The characteristic times for the slow kinetic phase were 8.3 ± 0.7 and 8.3 ± 2.1 hr (Table 1). The characteristic times of the slow phase of fluorescence change for the different W144 and W197 mutant variants were comparable, and depended on the total protein concentration (while keeping the doping ratio fixed at 1:50), as expected for an assembly reaction (Figure 4—figure supplement 1). In contrast, when a doping ratio of 1:99 was used (while keeping the total protein concentration fixed), the characteristic times remained unchanged for both the unlabelled W144-C153 and W197-C223 mutant variants (Figure 4—figure supplement 2). These results indicated that the slow change in Trp fluorescence also accompanied the formation of co-oligomers, irrespective of the position of Trp in the monomer.

Table 1. Summary of the characteristic times of misfolding/oligomerization monitored by far-UV CD, tryptophan fluorescence and site-specific intra-molecular FRET.

Dopant protein Characteristic time of fluorescence change (h) Characteristic time of FRET change (h)
W144-C153 8.3 ± 1.3 7.1 ± 0.1
W144-C153-TNB 10.0 ± 1.0
W144-C199 6.7 ± 2.7 3.3 ± 0.7
W144-C199-TNB 6.3 ± 0.8
W144-C223 10.0 ± 1.0 Not determinable
W144-C223-TNB 5.9 ± 1.7
W197-C169 8.3 ± 0.7 1.7 ± 0.2, 16.7 ± 2.8
W197-C169-TNB 2.3 ± 0.1
W197-C223 8.3 ± 2.1 1.4 ± 0.3, 11.1 ± 2.5
W197-C223-TNB 2.9 ± 0.1
CD monitored misfolding* 11.1 ± 3.7 -

*The characteristic time of the CD monitored misfolding was obtained by global fitting all the data in Figure 3A. Characteristic times were determined for a mixture of 2 mol% dopant protein and 98 mol% Trp-less moPrP. Error bars are standard deviation of the mean, determined from three to five independent measurements, on separate samples.

In contrast, the burst phase change in Trp fluorescence, which was seen when a W197-containing mutant variant was the dopant protein, was complete before co-oligomer formation had commenced, with an amplitude which was independent of the total protein concentration, suggesting that it was an intramolecular change (Figure 4—figure supplement 1).

Site-specific conformational changes in moPrP monitored by intra-molecular FRET

Finally, the kinetics of intra-molecular changes across the structured CTD of moPrP were measured using FRET. Each unlabelled protein and its corresponding TNB-labelled counterpart was used as a dopant and was co-oligomerized separately with Trp-less moPrP at a 1:50 doping ratio. The amplitude and characteristic times of fluorescence change were both distinct for the corresponding labelled proteins. The data suggested that two of the distances monitored in these experiments, changed in a manner comparable to each other, but distinct from the other three distances (Figure 4).

Since changes in both distance R and Forster radius R0 can affect the FRET efficiency, E, (Equation 3) it was important to consider both, while interpreting changes in E. It is to be noted that an increase in the quantum yield as well as a blue shift of the spectrum of the donor W144 is expected to increase R(Lakowicz, 2006), although not to a significant extent, due to its 1/6th power dependence on both the quantum yield and the overlap integral (Equation 4). An increase in R0 was expected to result in an increase in E, but for both FRET pairs W144-C153 and W144-C199, a decrease in E was observed. Consequently, the decrease in E reflected a true increase in distance. In contrast, for the TNB-labelled W197-C169 and W197-C223 mutant variants (Figure 4, Appendix 1, Figure 4—figure supplement 3 and Supplementary file 1), the very small changes in quantum yield and overlap integral upon oligomerization result in only a 2.5–4% decrease in R0 (Equations 3 and 4). The modest change in R0 could only account for 8–23% of the total change in FRET efficiency observed for these proteins, suggesting that the decrease in E must be a consequence of a true change in distance. Moreover, a change in κ2 also could not account for the observed change in FRET efficiency (Appendix 1, Figure 4—figure supplement 4 and Supplementary file 5).

For the W144-C153 FRET pair, designed to monitor conformational changes in α1, the intra-molecular FRET efficiency decreased by ~22% with a characteristic time of 7.1 ± 0.1 hr (Figure 4F and Table 1). Among the two FRET pairs designed to monitor subdomain separation, W144-C199 decreased by ~54% with a characteristic time of 3.3 ± 0.7 hr (Figure 4G and Table 1), whereas W144-C223 did not show an observable change in intra-molecular FRET efficiency (Figure 4H). This could be because either the distance remained unchanged, or became greater than the sensitivity range (~11 Å to ~35 Å) of the Trp-TNB FRET pair.

The intra-molecular FRET efficiency for both FRET pairs with W197 as the donor fluorophore, W197-C169 and W197-C223 changed in a manner distinct from that of the other FRET pairs. First, the amplitude of the burst phase change in Trp fluorescence was comparable for both the unlabelled and labelled proteins, indicating that no change in intra-molecular FRET efficiency occurred in the dead time of measurement. This further confirmed that the burst-phase change in fluorescence reflected only a localized perturbation to the environment of W197, before oligomerization commenced.

Second, the FRET efficiency changed in two observable kinetic phases: a fast phase during which intra-molecular FRET efficiency increased and a slow phase during which it decreased. The apparent fast compaction of the sequence segments spanning both α2 and α3, as seen in the increase in FRET efficiency, appeared to take place with characteristic times of 1.7 ± 0.2 and 1.4 ± 0.3 hr, respectively (Table 1). The apparent fast increase in FRET efficiency, was more than 30-fold faster than the estimated timescale for the independent oligomerization of 2 μM labelled dopant protein (Sabareesan and Udgaonkar, 2016), and thus, the fast phase of FRET efficiency increase did not originate from (i) the oligomerization of 2 μM labelled dopant proteins independently of 98 μM Trp-less moPrP, or (ii) co-oligomerization of the two proteins on a faster timescale (see above). Furthermore, the fast compaction of the erstwhile helical sequence segments was also observed for a Trp-197-DNP-C2 FRET pair (with a R0 of ~30 Å) and for a Trp-DANS FRET pair (Appendix 1 and Figure 4—figure supplement 3). The characteristic times for the slow phase of elongation/FRET decrease (16.7 ± 2.8 and 11.1 ± 2.5 hr) were comparable to the characteristic time of global misfolding, as monitored by far-UV CD (11.1 ± 3.7 hr) (Figure 3A and Table 1).

With the exception of W144-C153-TNB, all other TNB-labelled proteins, at 100 μM concentration, by themselves misfolded with characteristic times of ~1.5 hr, when monitored by CD (Supplementary file 2). Nevertheless, the oligomerization reactions in which these proteins were used (at 2 μM concentration) as dopants of 98 μM Trp-less moPrP took place with characteristic times ranging between ~2 and 10 hrs, when monitored by fluorescence (Figure 4 and Table 1). Moreover, even though the 100 μM DANS-labelled proteins by themselves misfolded with a characteristic time of ~0.5 hr (Supplementary file 2), which was ~2.5 fold faster than the corresponding TNB-labelled proteins, the observed characteristic times of fluorescence and FRET-monitored changes, when the DANS-labelled proteins were used as dopant proteins, were in qualitative agreement with those of the corresponding TNB-labelled proteins (Figure 1—figure supplement 2, Figure 4—figure supplement 3 and Supplementary file 2). The lack of correlation between the timescales of misfolding of the labelled proteins by themselves, and timescales when the same proteins were used as dopant proteins, suggests that the fast changes in FRET efficiency are unlikely to be a consequence of altered co-oligomerization kinetics of 98 μM Trp-less moPrP when it co-oligomerizes with 2 μM dopant.

Kinetic modelling of FRET and SEC data

Kinetic simulations and global fitting were carried out to test whether a parallel, sequential or triangular model best described the formation of OL and OS from M, taking into account both the SEC and FRET data. The criteria for choosing a suitable kinetic model were (i) it had to correctly predict the monomer loss kinetics determined from SEC; (ii) it had to correctly predict the concentrations of M, OL and OS at the end of 60 hr; and (iii) it had to correctly predict the experimentally observed FRET-monitored kinetics, by taking the sum of the FRET efficiencies of M, OL and OS weighted by their populations.

The parallel OS ↔ M ↔ OL model and the sequential M ↔ O↔ OL model could not satisfy all three criteria adequately, but the sequential M ↔ O↔ OS model could do so. This model predicted that M oligomerizes reversibly to form OL, which then disaggregates reversibly to form OS, with characteristic times (1/k) for the M → OL, OL → M, OL → OS and OS → OL transitions, of 11.1, 20, 11.1 and 33.3 hr, respectively. It should be noted that in a previous study (Jain and Udgaonkar, 2011), OL had been shown to be capable of disaggregating to OS. Global fitting of all the FRET data further predicted that (i) for the sequence segments 197–169 and 197–223, the FRET efficiency values are higher in OL than in OS, and that (ii) for the 144–153 and 144–199 segments, the FRET efficiency values are lower in OL and OS than in M (Figure 5 and Table 2). It should also be noted that in the kinetic models, it was assumed that all the transitions were first-order transitions. This assumption was made because the observed kinetics measured by CD, steady-state Trp fluorescence anisotropy, and by SEC, for all the unlabelled and labelled protein variants, were found to be describable well by a single exponential equation, even though only the two dissociation transitions (OL → M and OL → OS) are first-order transitions, while the association transitions are obviously not.

Figure 5. Kinetic model for misfolded oligomer formation of moPrP at pH 4 in the presence of 150 mM NaCl.

Figure 5.

(A) OL forms reversibly from M with forward and backward rate constants of 0.09 ± 0.02 and 0.05 ± 0.01 h−1, respectively, and subsequently reversibly dissassembles to form OS with forward and backward rate constants of 0.09 ± 0.03 and 0.03 ± 0.01 h−1, respectively. (B) Normalized monomer loss kinetics accompanying oligomerization of 100 µM Trp-less moPrP. The red line through the data is the fit of the experimental data to the model in (A). (C-F) Site-specific misfolding kinetics monitored by FRET efficiency as described in Figure 4. The red line through the data is the fit of the experimental data to the model in (A). The FRET efficiencies of M, OL and OS for each sequence segment, as estimated from the global fitting routine are tabulated in Table 2.

Table 2. Summary of the FRET efficiencies of M, OL and OS obtained from global fitting of FRET data.

Sequence segment FRET efficiency (M) FRET efficiency (OL) FRET efficiency (OS)
144–153 0.77 ± 0.01 0.50 ± 0.03 0.59 ± 0.02
144–199 0.57 ± 0.01 1e-7±1e-13 0.28 ± 0.03
197–169 0.07 ± 0.01 0.16 ± 0.01 1e-20 (constrained)
197–223 0.17 ± 0.01 0.21 ± 0.02 0.06 ± 0.02

*The FRET efficiencies were obtained by global fitting the data from Figure 4. The FRET efficiencies of M, OL and OS was allowed to vary locally in each case, except in the case of sequence segment 197–169, where the FRET efficiency of OS had to be constrained to a low value of 1e-20 for an acceptable fit to the data. Errors in the FRET efficiency are standard errors from the fitting routine.

A triangular mechanism, in which both OS and OL can form reversibly from M, and OS and OL also equilibrate with each other, was also tested. Kinetic simulations according to the triangular mechanism also described all aspects of the data well, and all criteria were met. The forward and backward apparent rate constants for the M ↔ OS step, were however more than 10-fold slower than the all other apparent rate constants, indicating that negligible fraction of the OS oligomers formed directly from M. It is more appropriate to use the M ↔ OL ↔ OS mechanism, because it is a simpler kinetic model than the triangular model.

Discussion

The global stability, misfolding and oligomerization of WT moPrP is pH dependent. At pH 4 and 7, ΔG has been reported to be 4.6 and 6.04 kcal mol−1 respectively. Moreover, it has been shown that while misfolding/oligomerization is 100% complete within 24 hr at pH 4, it is only ~5% complete at pH 5.7 on the same timescale (Singh et al., 2014; Singh and Udgaonkar, 2016a). Linear extrapolation to pH 7 suggests that misfolding/oligomerization should take years to complete at neutral pH. It should be noted that at pH 7, moPrP forms amyloid fibrils, and that oligomers are either completely absent or present in undetectable amounts (Singh and Udgaonkar, 2013).

Previous real-time NMR measurements had not detected any major structural rearrangement in the monomer, prior to oligomerization at pH 4 in the presence of 150 mM NaCl. This was supported by CD, SEC and HX-MS measurements of changes in conformation and size/population during oligomerization, under similar conditions, which had also indicated that major conformational change accompanying misfolding occurs only after, or concomitant with oligomerization. Among the two tryptophan residues, W144 and W197 that were used as donor fluorophores in this study, W197-containing mutant variants exhibited a burst-phase change in fluorescence, when they were used as dopant proteins in co-oligomerization experiments. This is likely a consequence of a local change in monomeric moPrP before the start of oligomerization, namely the disruption of the K193-E195 salt-bridge in the α2-α3 loop, in accordance with previous NMR measurements (Sengupta et al., 2017).

To probe the major conformational changes in the monomeric unit as it misfolds into β-sheet-rich oligomers in real time with segment-specific resolution, FRET measurements were employed. The presence of eight tryptophan residues in WT moPrP prevented its use in suppressing the intermolecular contributions to the FRET signal during oligomer formation. Trp-less moPrP was therefore used as the pseudo-WT moPrP analogue for the FRET measurements. The secondary structure and size (as estimated from CD and DLS measurements, respectively) (Sengupta and Udgaonkar, 2017) of the Trp-less moPrP oligomers were found to be comparable to that of WT moPrP (Figure 1—figure supplement 2). Moreover, Trp-less moPrP formed oligomers L and S (OL and OS) to similar extents as did WT moPrP at pH 4 in 150 mM NaCl. However, Trp-less moPrP misfolded and oligomerized ~2.5 fold slower compared to that of WT moPrP (Figure 1—figure supplement 2 and Supplementary file 2). With this caveat in mind, the FRET measurements have allowed the delineation of the major structural changes that take place in the monomer, as it converts into soluble β-sheet-rich oligomers at pH 4.

A qualitative comparison of the characteristic times of all structural changes monitored by FRET suggests that a compaction of the segments spanning the α2 and α3 helices is the fastest change (Table 1). The separation of the β1-α1-β2 sub-domain from the α2-α3 subdomain and the conformational change in α1 appear to be slower. The slow decrease in FRET efficiency in α1 is likely to be due to the unfolding of this helix (Singh and Udgaonkar, 2015a). Remarkably, these results suggest that domain separation occurs spontaneously under acidic conditions which mimic the endocytic environment in the cell, in marked contrast to previous results where oligomerization was induced by thermal denaturation (Eghiaian et al., 2007). Moreover, this study shows that it is possible to directly show that the β1-α1-β2 sub-domain separates from the α2-α3 subdomain during the formation of the misfolded oligomers, by using an appropriately placed FRET donor-acceptor pair. In previous studies, the importance of subdomain separation had been inferred only indirectly from the observation that disulfide-crosslinking of the subdomains can abolish oligomerization (Hafner-Bratkovic et al., 2011). The slowest change appears to be the elongation of sequence segments that had spanned α2 and α3; this is possibly due to their conversion into β-sheets and is also reported on by the global probe CD (Figure 6).

Figure 6. Model depicting the site-specific misfolding moPrP at during the course of oligomer formation at pH 4.

Figure 6.

The sequence segments spanning the α2 and α3 helices undergo a compaction as monomers convert reversibly to large oligomers, OL. As oligomers OL disassemble reversibly to form small oligomers, OS, the compact sequence segments spanning the erstwhile α2 and α3 helices elongate into extended β-strands. The α1-β1-β2 and α2-α3 subdomains are separated, and α1 is unfolded in both OL and OS, but to variable extents. The NTR region is not shown for clarity. The disulphide bond is shown as black sticks. The transparent subunits in the growing oligomer represent the co-oligomerizing Trp-less moPrP which does not contribute to the FRET signal at any time during the oligomerization reaction. The figure is not drawn to scale.

From the FRET measurements reported here, the sequence segment spanning α3 appears to undergo a fast compaction and a slow elongation, as does the sequence segment spanning α2. In contrast, HX-MS experiments could not detect any significant conformational change in this segment upon oligomer formation: α3 was found to be highly protected against HX in both the monomer and oligomer (Sabareesan and Udgaonkar, 2016; Singh and Udgaonkar, 2015a). HX-MS measurements probe the extent of exchange of backbone amide protons/deuterons with solvent and are silent to structural changes, which do not result in a measurable change in protection against HX. Since α3 is part of the buried core of both the monomer and the oligomer, HX-MS fails to detect conformational changes which might be taking place in α3, concomitant to oligomer formation. FRET, on the other hand, can detect these structural changes readily. This explains the apparent discrepancy between the HX-MS and FRET monitored conformational changes in α3 during the course of oligomer formation. Importantly, these results are in contrast to EPR studies carried out at neutral pH, on disulfide-free mutant variants of the PrP in nanodiscs, which had suggested that α1 and α3 retain their helicity, and that only α2 undergoes conversion to the β-conformation (Yang et al., 2015).

The observations from the SEC experiments that both large (OL) and small (OS) oligomers are formed sequentially from monomer M, and that both oligomers and monomer coexist at equilibrium at pH 4 in the presence of 150 mM NaCl, along with the previous demonstration that OL can disaggregate into OS (Jain and Udgaonkar, 2010) allowed kinetic modelling of the SEC data according to a M ↔ O↔ OS mechanism. The kinetic modelling and global fitting of the SEC and FRET data together yielded forward and backward rate constants for each step. Specifically and importantly, the biphasic (increase followed by decrease) changes in FRET efficiency observed for the sequence segments 197–169 and 197–223 were found to be a consequence of higher FRET efficiency values in OL than in M and OS. In addition, the decrease in FRET efficiency observed for sequence segments 144–153 and 144–199 was found to be a consequence of lower FRET efficiency values in OL and OS than in M (Table 2).

Hence, the kinetic modelling indicates that the structural changes accompanying oligomerization occur in two steps. The formation of OL from M is accompanied by compaction of the sequence segments spanning the α2 and α3 helices, which accounts for the higher FRET efficiency seen for sequence segments 197–169 and 197–223 in OL. The subsequent dissociation of OL to OS is accompanied by an expansion of the same sequence segments, which is likely to be due to the formation of extended β-sheet structure in OS. It is possibly the formation of β-sheet structure that makes OS more stable than OL. The estimated FRET efficiency values for the sequence segments 144–153 and 144–199 further predict that α1 has unfolded and the erstwhile β1-α1-β2 sub-domain has separated from the erstwhile α2-α3 sub-domain to different extents in OL and OS. These observations are supported by previous HX-MS measurements of the oligomers at pH 2 which showed that the sequence stretch 190–197 spanning a segment of the α2 helix and the α2- α3 loop is weakly protected in OL, but moderately protected in OS, suggesting that the α2 helix is unstructured in OL, but may have converted to β-sheet in OS (Singh et al., 2012). Moreover, the α1 helix is weakly protected in OL, but moderately protected in OS in accordance with the FRET results.

For an α-helix to convert into a β-sheet, intra-helical hydrogen bonds must be disrupted, for new inter-strand hydrogen bonds to form. It has been suggested that helices must undergo partial or complete unfolding before they can re-arrange their hydrogen bond structure to form β-sheets (Ding et al., 2003; Qin and Buehler, 2010). In the case of moPrP, hydrogen bonding at both the ends and/or middle of α2 and α3 can dissolve, but due to the presence of the native disulfide bond, residual structure will still be present. This increase in dynamics, without the complete loss of structure might allow the two ends of the helices to come closer, leading to the modest increase in FRET efficiency, distinct from the random coil structure of completely unfolded segments, which typically have lower FRET efficiencies than their folded counterparts. Subsequently, the formation of new hydrogen bonds between β-strands within and between monomers (leading to a decrease in FRET efficiency as β-strands are usually longer than α-helices) is complete within a timescale that is similar to that of global misfolding monitored by far-UV CD. The presence of highly dynamic and frustrated sequence segments like the TVTTTT stretch at the C terminal end of α2, possibly aids the early partial unfolding/compaction (Chen and Thirumalai, 2013). On the other hand, the disulphide bond stapling α2 and α3 might be a deterrent to complete unfolding, but could be crucial in positioning the two helices in an optimal position for inter-strand hydrogen bond formation. Alternatively, the compaction could be also be a result of non-native hydrogen bond formation which neither mimics the α-helix or β-sheet arrangement. Indeed, folding simulations of α-helix formation have detected misfolded β-hairpin like structures and compact structures with non-native hydrogen bonds (Bertsch et al., 1998; Lin et al., 2014).

In conclusion, the data presented here is the first real-time experimental demonstration of the sequence of segment-specific conformational changes that occur in each monomeric unit of moPrP as it forms oligomers. It will be important to establish whether the compaction-elongation mechanism of the α to β switch, delineated here for moPrP at pH 4, is shared by other proteins that undergo a similar conformational change during aggregation. Finally, the search for new molecules with the potential to completely abolish misfolding can benefit greatly from studies probing the effect of pathogenic mutations and anti-prion drugs on each of the multiple conformational changes delineated in this study, which lead to global misfolding.

Materials and methods

Key resources table.

Reagent type
(species) or resource
Designation Source or reference Identifiers Additional information
Recombinant DNA reagent Trp-less-moPrP (pET22b vector) https://doi.org/10.1016/j.pep.2017.07.014 NA Novagen-Sigma Aldrich
Recombinant DNA reagent W144-C153-moPrP (pET 22b vector) https://doi.org/10.1016/j.pep.2017.07.014 NA Novagen-Sigma Aldrich
Recombinant DNA reagent W144-C199-moPrP (pET22b vector) https://doi.org/10.1016/j.pep.2017.07.014 NA Novagen-Sigma Aldrich
Recombinant
DNA reagent
W144-C223-moPrP (pET22b vector) https://doi.org/10.1016/j.pep.2017.07.014 NA Novagen-Sigma Aldrich
Recombinant DNA reagent W197-C169-moPrP (pET22b vector) https://doi.org/10.1016/j.pep.2017.07.014 NA Novagen-Sigma Aldrich
Recombinant DNA reagent W197-C223-moPrP (pET22b vector) https://doi.org/10.1016/j.pep.2017.07.014 NA Novagen-Sigma Aldrich
Peptide, recombinant protein Trp-less-moPrP https://doi.org/10.1016/j.pep.2017.07.014 NA
Peptide,
recombinant protein
W144-C153-moPrP https://doi.org/10.1016/j.pep.2017.07.014 NA
Peptide, recombinant protein W144-C199-moPrP https://doi.org/10.1016/j.pep.2017.07.014 NA
Peptide, recombinant protein W144-C223-moPrP https://doi.org/10.1016/j.pep.2017.07.014 NA
Peptide,
recombinant protein
W197-C169-moPrP https://doi.org/10.1016/j.pep.2017.07.014 NA
Peptide, recombinant protein W197-C223-moPrP https://doi.org/10.1016/j.pep.2017.07.014 NA
Software, algorithm DynaFit https://doi.org/10.1006/abio.1996.0238 NA

Reagents

All reagents used for experiments were of the highest purity grade from Sigma, unless otherwise specified. Urea was purchased from USB, and GdnHCl for protein purification from HiMedia. 2,4 DNP (dinitrophenyl C2 maleimide) was purchased from Anaspec.

Protein expression and purification

Five single Trp, single Cys-containing constructs, and a Trp-less construct were used in these experiments. The cloning, expression and purification of these proteins have been described elsewhere (Sengupta and Udgaonkar, 2017). The correct mass of all the constructs was verified by ESI-MS mass spectrometry (Appendix 1, Figure 1—figure supplement 1).

Labelling of single Trp, single Cys-containing moPrP with non-fluorescent acceptor thionitro benzoate (TNB), dinitrophenyl (DNP) or fluorescent 5-((((2-Iodoacetyl)amino)ethyl)amino)Naphthalene-1-Sulfonic Acid) (DANS)

Briefly, purified single Trp, single Cys-containing mutant variants were reduced with a 10-fold excess of TCEP, for 12 hr at 4°C under native conditions (in 10 mM NaOAc, pH 4) to remove any glutathione covalently linked to the extra cysteine. For a buried cysteine such as C153, the reduction reaction on the native protein was carried out for 36 hr. The protein was then either purified a second time by cation-exchange chromatography and dialysis against MQ water at 4°C to yield the unlabelled mutant variant, or processed further for labelling with TNB or DNP.

The protein, after reduction, was diluted with 20 mM Tris, pH 7.5, such that the final concentration of the protein during labelling was no more than 0.5 mg/ml. This was followed by the drop-wise addition of 50-fold excess of DTNB in 20 mM Tris, pH 7.5, while continuously stirring. For labelling with 2,4-DNP, a concentrated stock solution of 2,4-DNP in DMSO was added drop-wise to the dilute protein solution, in 20 mM Tris, pH 7.5, while stirring. The labelling reaction was allowed to proceed for 12 to 36 hr at 4°C (depending upon the extent of burial of the cysteine residue). For labelling with IAEDANS, a total protein concentration of 25 µM and a 1.5–2 fold excess of dye was used, to avoid non-specific labelling of lysines. Some protein was found to precipitate during the labelling reaction, which was removed by centrifugation at 18,000 rpm. The supernatant, containing the labelled protein of interest was purified with a 5 ml FF-CM Sepharose (GE Healthcare) cation-exchange column. This was followed by extensive dialysis against MQ water after which the protein was flash-frozen and stored at −80°C until further use. The extent of labelling with TNB/DNP/DANS was found to be ≥95% for all but one mutant variant, from ESI-MS mass spectrometry (Appendix 1, Figure 1—figure supplement 1). The only exception was W197-C223-DANS, which was labelled to an extent of 85%. All labelled proteins were found to have an intact native disulphide bond. Only one labelled moiety was found to be present on each of the labelled mutant variants. The concentration of the labelled proteins was estimated from their absorbance at 280 nm, after correcting for the contribution of the dye (estimated from the absorbance) as described in the manufacturer’s protocol.

Equilibrium unfolding monitored by far-UV CD

Urea-induced equilibrium unfolding of all mutant variants in their unlabelled and labelled forms at pH 4, 25°C was monitored by far-UV CD at 222 nm. The corresponding thermodynamic stability, ΔG (kcal mol−1) and mid-point of unfolding, Cm (M) was obtained by fitting the fraction unfolded data versus denaturant concentration to a two-parameter equation (Agashe and Udgaonkar, 1995).

DLS measurements of WT and Trp-less oligomers

WT and Trp-less moPrP were oligomerized to form misfolded β-sheet-rich oligomers at pH 4 in the presence of 150 mM NaCl. The oligomers were diluted with 1X aggregation buffer to a final concentration of 10 μM for DLS measurements (Figure 1—figure supplement 2). DLS measurements were carried out as described earlier (Sengupta and Udgaonkar, 2017).

Global misfolding kinetics monitored by far-UV CD

The global misfolding kinetics of all unlabelled, labelled and Trp-less moPrP mutant variants were monitored by recording the far-UV CD signal at 228 nm. Misfolding and oligomerization were initiated by the addition of 10x aggregation buffer to monomeric protein initially present in 10 mM sodium acetate at pH 4. The final protein concentration was 100 µM, and the final buffer composition was 10 mM sodium acetate, 150 mM NaCl, pH 4 (1x aggregation buffer), 37°C. At each kinetic time point, the mixture of oligomers and monomers was diluted with 1x aggregation buffer, such that the protein concentration during measurement was 10 µM (Sengupta et al., 2017). The data were fit to a single exponential equation

y=y0+a(1ebt) (1)

to obtain the apparent rate-constants (Supplementary file 2).

Co-oligomerization with Trp- less moPrP to suppress inter-molecular contributions to FRET

Since intra-molecular conformational changes were to be monitored by FRET, it was necessary that all inter-molecular FRET be effectively suppressed. To achieve this, co-oligomerization of unlabelled and TNB-labelled W144-C153 moPrP variant with Trp-less moPrP in different doping ratios was employed. The total protein concentration in each oligomerization reaction was kept fixed at 100 µM. The concentration of the dopant, W144-C153 moPrP, was systematically varied from 100 to 2 mol%.

Misfolding kinetics of Trp-less moPrP doped with varying concentrations of W197-C223-TNB

To verify that at the low labelling densities employed in these experiments, the dopant and Trp-less protein form misfolded co-oligomers at a rate which is indistinguishable from the global misfolding kinetics of Trp-less moPrP alone, misfolding of Trp-less moPrP with dopant concentrations of 1, 2, 10 and 20 mol% (while keeping total protein concentration fixed at 100 µM) were measured by monitoring their misfolding kinetics by measuring the far-UV CD signal at 228 nm. The dopant, W197-C223-TNB was chosen because it misfolds almost ~10 fold faster by itself as compared to Trp-less moPrP.

Misfolding kinetics of Trp-less moPrP doped with 2 mol% of dopant

All unlabelled and TNB-labelled single Trp, single Cys-containing mutant variants (dopant proteins) were co-oligomerized with Trp-less moPrP, such that the total protein concentration was 100 µM and the dopant protein concentration in each reaction was 2 µM. The global misfolding kinetics was monitored by far-UV CD as described earlier.

Local stability measured using FRET ratio for the DANS-labelled mutant variants

Urea-induced local unfolding of W197-C169-DANS and W197-C223-DANS at pH 4°C and 25°C was monitored by monitoring the ratio of fluorescence intensities at 495 nm and 345 nm (F495/ F345), respectively, which are the intensity maxima for the IAEDANS and tryptophan fluorophores respectively, when the sample is excited at 295 nm (Figure 4—figure supplement 5). The excitation and emission slit widths were set at 1 and 5 nm respectively. The same samples were also used for the CD measurements (Figure 1—figure supplement 2). The corresponding local stability, ΔG (kcal mol−1) and mid-point of unfolding, Cm (M) was obtained by fitting the normalized data versus denaturant concentration to a six-parameter equation (Agashe and Udgaonkar, 1995).

Co-oligomerization kinetics of Trp-less moPrP doped with 2 mol% of dopant monitored by steady-state fluorescence anisotropy

W144-C153-TNB and W197-C223-TNB (dopant proteins) were co-oligomerized with Trp-less moPrP, such that the total protein concentration was 100 µM and the dopant protein concentration in each reaction was 2 µM. The co-oligomerization kinetics was monitored by steady-state tryptophan fluorescence anisotropy at an excitation wavelength of 295 nm and emission wavelength of 340 nm on a Fluorolog spectrofluorimeter with an excitation slit width and emission slit width of 5 nm respectively, and corrected using the G-factor determined for the instrument, every day (Figure 2C). The data were fit to a single exponential equation (Equation 1) to obtain the rate-constants (Supplementary file 4).

Oligomerization kinetics monitored by size-exclusion chromatography

100 µM Trp-less moPrP was oligomerized as described above. At each time point, 25 µL of the oligomerization mixture was mixed with 225 µL of 1X aggregation buffer, such that the total protein concentration was 10 µM. 200 µL of this mixture was injected into a Waters Protein Pak 300-SW column and the oligomerization kinetics monitored and the data analysed as described earlier (Sabareesan and Udgaonkar, 2016).

Kinetics of misfolding monitored by FRET

Every pair of unlabelled and labelled single Trp, single Cys-containing mutant variants was either individually co-oligomerized with Trp-less moPrP, or in its absence. The total protein concentration was fixed at 100 uM, with the dopant concentration at 2 µM for the former case, and only 2 µM for the latter case, in a reaction volume of 500 µL. All measurements were made on a Fluoromax 4 spectrofluorimeter. A quartz cuvette of path length 2 × 10 mm was used for all measurements. The temperature of the reaction was maintained at 37°C, with a circulating water bath. The cuvette was kept stoppered during the reaction to prevent solvent loss due to evaporation.

To eliminate the contribution of scatter to the fluorescence signal, a 325 nm long-pass filter was kept between the thermo-statted cuvette and the emission monochromator. An excitation wavelength of 295 nm, an emission wavelength of 340 nm, excitation slit width of 1 nm and emission slit width of 5 nm were used in all experiments. The kinetics mode of the Fluoresscence software was used for acquisition for most experiments. The number of cycles and time interval between cycles were set according to the number of kinetic data points and total acquisition time of the reaction. Every kinetic time point was an average of 10 points acquired over 10 s. The anti-photobleaching mode was activated in these experiments, such that the shutter remained closed between acquisitions, so that negligible loss of fluorescence intensity due to photobleaching occurs. Every experiment was repeated 4–5 times on an average. For some experiments, kinetic time points were acquired manually, at desired intervals. A control experiment was carried out using the same acquisition parameters, but in the presence of native buffer only (10 mM sodium acetate, pH 4). The signal was found to remain constant over a period of 30 hr indicating no photo-bleaching was taking place (Appendix 1, Figure 4—figure supplement 1A).

The fluorescence emission spectra of the protein(s) were recorded before and every oligomerization reaction. First, the two proteins were mixed such that the concentration of Trp- less moPrP and dopant were 109 and 2.2 µM, respectively, in 10 mM sodium acetate, pH 4 buffer. This was incubated for 5 min in the thermostatted cuvette before recording the spectrum. The fluorescence intensity of the monomer was adjusted for concentration by multiplying the measured value at 340 nm by 0.9. These concentrations were chosen such that after addition of 50 µL of 10x aggregation buffer to 450 µL of the above protein mixture, the final concentrations of Trp-less moPrP and dopant would be 98 µM and 2 µM, respectively.

Similarly, before recording the first kinetic time point after initiation of misfolding, a dead time of 5 min was allowed for equilibration to 37°C. For background correction, the intensity corresponding to 98 µM Trp-less moPrP in the same buffer conditions was subtracted from each data point in the doped samples. The background value was found not to change with time, showing that contribution due to scatter was indeed negligible, and that the Trp-less protein preparation was free from tryptophan contamination. The data were normalized to the signal for the corresponding donor-only sample at t = 0, FD(0), for all samples. FRET at every kinetic time point was calculated according to the following formula:

E(t)=1FDA(t)FD(t) (2)

 where FD and FDA are the fluorescence emission intensity values for the donor-only, and donor acceptor sample, respectively, at each kinetic time point t.

FRET efficiency is described by the equation:

E=11+(R/R0)6 (3)

 where R is the distance between the donor and the acceptor and the Foster Radius, R0 is the distance, at which E is 0.5.

Foster Radius, R0 is described by the equation:

R0=0.211(κ2QYn4J(λ))16 (4)

where κ2 is the orientation factor between the donor and acceptor dipoles, QY is the quantum yield of the donor, n is the refractive index of the medium and J(λ) is the overlap integral between the fluorescence emission spectrum of the donor and the absorption spectrum of the acceptor (Lakowicz, 2006). Similar fluorescence measurements were made for the 1:99 samples corresponding to doping with 1 mol% dopant protein.

Global fitting to parallel and sequential models of oligomerization

Global fitting was carried out with the program DynaFIT (Kuzmic, 1996). Briefly, parallel and sequential reaction schemes were tested for the reversible formation of oligomers Os and OL from M. The ratios of forward and backward rate constants were fixed to account for the ratio of Os/OL ~ 3 and the amounts of M, OL and Os that was approximately estimated from the SEC data. The FRET and SEC data were globally fit separately to first test which of the reaction schemes best describes both data sets with comparable rate constants. While the M ↔ O↔ OL and the O↔ M ↔ OL mechanisms were able to fit the FRET and SEC data separately to satisfaction, global fitting of both data sets together did not yield acceptable fits. All parameters were allowed to vary in the fitting procedure except for the FRET efficiency value of OS for the 197–169 sequence segment, which was constrained to a low value of 1e-20 while global fitting of FRET data to the M ↔ O↔ OS mechanism. While fitting the normalized monomer loss kinetics from the SEC data, the signal for M was allowed to vary, while the signal for OS and OL were fixed to zero.

Acknowledgements

We thank members of our laboratory for critically reading the manuscript, and MK Mathew, S Gosavi, A Singh and S Krishna for helpful discussions. We thank Sandhya Bhatia for help with the time-resolved anisotropy measurements and analysis. We thank Harish Kumar for collecting the DLS data for the moPrP oligomers. We thank Roumita Moulick for providing some of the constructs used in this study. We thank Prashant N Jethva, Pooja Malhotra and Rupam Bhattacharya for the ESI-MS measurements. JBU is a recipient of a JC Bose National Fellowship from the Government of India, and IS is a recipient of the Innovative Young Biotechnologist Award from the Department of Biotechnology, Government of India. This work was funded by the Tata Institute of Fundamental Research and by the Department of Biotechnology, Government of India.

Appendix 1

Supplementary materials

Estimation of range of κ2 values for the oligomeric forms of W197-containing mutant variants

Since it is not possible to measure the exact value of κ2, a range of κ2 values for both W197-containing mutant variants, W197-C169 and W197-C223 in their oligomeric forms were determined from time-resolved anisotropy measurements (Figure 4—figure supplement 4 and Supplementary file 5). TNB is non-fluorescent; therefore, the proteins were labelled with 1,5-IAEDANS (see Materials and methods section) and measurements were made as described in Jha and Udgaonkar (2009).

The estimated κ2 values range from 0.4 to 2 and 0.21 to 2.5 for the proteins W197-C169 and W197-C223 respectively in their oligomeric forms. These values correspond to R0 values ranging from 23.8 to 31.1 and 21.3 to 32.2 Å respectively (Equation 4 in main text). If the FRET efficiency changes were only due to a change in R0 without any change in distance R, the expected FRET efficiency values should range from 0.04 to 0.25 and 0.05 to 0.36 for the W197-C169 and W197-C223 proteins in their oligomeric forms respectively. The lower observed FRET efficiencies of 0.01 and 0.035 respectively for these proteins (Figure 4—figure supplement 3) cannot be a consequence of a change in κ2 and R0 solely, and must reflect a true change in distance R.

Moreover, the fundamental anisotropy values of 0.24 and ~0.28 respectively estimated from the fit (r(0)) are significantly lower than the fundamental anisotropies of both donor tryptophan (r0 = 0.4) and acceptor 1,5-IAEDANS (r0 = 0.36) groups determined in frozen solution, suggesting a significant amplitude (40–50%) for the free motion of both donor and acceptor probes (Figure 4—figure supplement 4 and Supplementary file 5), even when attached to a large oligomeric species (Lakowicz, 2006; Lakshmikanth et al., 2001).

Therefore, (i) the fast sub-ns segmental motions of 40–50% amplitude of both donor and acceptor groups in the oligomeric forms of both proteins, (ii) the smaller size of the TNB label compared to the DANS label (iii) the inability of a change in κ2 and R0 to account for the observed FRET efficiency values in the oligomeric forms all justify the use of κ2 = 2/3 for the oligomeric forms.

Effect of mutation and labelling on secondary structure, stability and global misfolding kinetics

The secondary structure, thermodynamic stability and global misfolding kinetics of all the unlabelled and TNB/DANS-labelled mutant variants were determined experimentally using far-UV CD (Figure 1—figure supplement 2 and Supplementary file 2). For the WT moPrP, the values reported here agree well with previously reported values at pH 4 of 4.1 kcal mol−1, 1.2 kcal mol−1 M−1 and 3.5 M for ΔG, m and Cm respectively (Cereghetti et al., 2003). Most mutations in moPrP, which have been shown to alter the thermodynamic stability or folding/unfolding kinetics, have typically been located in buried positions in the α2-α3 subdomain, and involve hydrophobic side-chains (Hart et al., 2009). Keeping this in mind, all mutations were made in solvent-exposed positions, except for the completely buried M153C mutation in α1 and the partially-buried F197W mutation in the loop between α2 and α3 helices. The unlabelled W197-C169 and W197-C223 mutant variants used here were not destabilized, supporting earlier observations that the F197W mutation does not perturb stability and/or unfolding/folding kinetics despite it being equivalent to residue F198 in human PrP, a site for the pathogenic mutation F198S associated with the inherited prion disease, the GSS syndrome (Jenkins et al., 2008). However, the W197-C169 mutant variant misfolded with slightly faster kinetics, compared to the WT moPrP, possibly due to its location in the loop between β2 and α2 (Agarwal et al., 2015; Gossert et al., 2005). Somewhat counter intuitively, the completely buried M153C mutation in α1 did not alter thermodynamic stability or global misfolding kinetics. The only mutant variant with a significant reduction in thermodynamic stability (but without a change in global misfolding kinetics) was W144-C199, (despite E199C being a solvent-exposed position) possibly due to an altered surface charge. A change in intrinsic properties of the amino acid sequence (for e.g. hydrophobicity, β-sheet propensity or charge) upon mutation could not account for the change in the global misfolding kinetics (Figure 4—figure supplement 5).

In marked contrast to the unlabelled mutant variants, a striking correlation between the global misfolding kinetics and position of the TNB/DANS acceptor moiety was seen for the corresponding labelled mutant variants (with no correlation to thermodynamic stability) at 100% labelling density. When the solvent-exposed positions C169, C199 or C223, in the α2-α3 subdomain were covalently modified with TNB/DANS, global misfolding kinetics was accelerated. In contrast, when the buried position C153 on α1 was covalently modified with TNB, global misfolding kinetics remained unchanged. The enhanced kinetics is unlikely to be due to a change in local stability of the α2 and α3 helices upon labelling (Figure 4—figure supplement 5 and Supplementary file 2), but instead appears to be a result of enhanced association kinetics at high labelling densities. This is possibly because the formation of misfolded oligomers of moPrP at pH 4 is rate-limited by association (Sengupta et al., 2017), and involves inter-molecular interactions within the α2-α3 subdomain of monomeric PrP, which misfolds to form the β-rich core of the oligomers.

Correlation of global misfolding rates with change in intrinsic properties, local and global thermodynamic stability upon mutation/labelling

An increase in protein misfolding/aggregation rates have been shown to correlate well with an increase in hydrophobicity, β-sheet propensity, population of aggregation-prone intermediates (Chiti et al., 2003; Chiti et al., 2002b; Dobson, 2003), a decrease in charge (Calamai et al., 2003; Chiti et al., 2002a) and/or local/global thermodynamic stability (Chiti and Dobson, 2006). The hydrophobicity and β-sheet propensities reported in Chiti et al. (2003) were used for this analysis. p-values>>0.05 suggested that the global misfolding rate of the labelled and unlabelled mutant variants used in these studies have no significant correlation with any of these properties (Figure 4—figure supplement 5). Moreover, local stabilities of the α2 and α3 helices determined by the FRET ratio (F495/ F345) in the corresponding DANS-labelled mutant variants (Figure 4—figure supplement 5 and Supplementary file 2) was found to be in good agreement with the mean ΔGop of ~3.4 ± 0.7 kcal mol−1 and ≥2.6 ± 1.5 kcal mol−1, across the slowest exchanging residues of the α2 and α3 helices, determined previously from HX-MS and NMR for WT moPrP (Moulick et al., 2015; Singh and Udgaonkar, 2016b). Therefore, a reduction of local stability was also not able to account for the faster misfolding rates for some mutant variants.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Ishita Sengupta, Email: ishita@iitk.ac.in.

Jayant Udgaonkar, Email: jayant@iiserpune.ac.in.

Andreas Martin, University of California, Berkeley, United States.

John Kuriyan, University of California, Berkeley, United States.

Funding Information

This paper was supported by the following grants:

  • Department of Biotechnology, Ministry of Science and Technology JC Bose Fellowship to Jayant Udgaonkar.

  • Department of Biotechnology, Ministry of Science and Technology IYBA to Ishita Sengupta.

  • Tata Institute of Fundamental Research to Jayant Udgaonkar.

Additional information

Competing interests

No competing interests declared.

Author contributions

Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing.

Conceptualization, Resources, Software, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing.

Additional files

Supplementary file 1. Parameters used for the estimation of FRET efficiency in monomeric moPrP mutant variants.
elife-44698-supp1.docx (14.7KB, docx)
DOI: 10.7554/eLife.44698.021
Supplementary file 2. Thermodynamic parameters obtained from urea-induced equilibrium unfolding of different moPrP variants at pH 4 and their misfolding rate constants monitored by far-UV CD at 228 nm, for 100 µM protein.
elife-44698-supp2.docx (14.7KB, docx)
DOI: 10.7554/eLife.44698.022
Supplementary file 3. Misfolding rate constants for Trp-less moPrP alone, 197–223-TNB alone and Trp-less moPrP doped with 1 mol %, 2 mol %, 10 mol % and 20 mol % of 197–223-TNB, monitored by far-UV CD at 228 nm.

The total protein concentration in each case was 100 µM.

elife-44698-supp3.docx (13.6KB, docx)
DOI: 10.7554/eLife.44698.023
Supplementary file 4. Apparent rate constant of co-oligomerization monitored by steady-state tryptophan fluorescence anisotropy at different dopant concentrations.
elife-44698-supp4.docx (13.7KB, docx)
DOI: 10.7554/eLife.44698.024
Supplementary file 5. Rotational correlation times, amplitudes and fundamental anisotropy r(0) values derived from fitting the time-resolved anisotropy data of 1,5-IAEDANS-labelled W197-containing mutant variants in the monomeric and oligomeric forms.
elife-44698-supp5.docx (13.9KB, docx)
DOI: 10.7554/eLife.44698.025
Transparent reporting form
DOI: 10.7554/eLife.44698.026

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 3 and 4.

References

  1. Agarwal S, Döring K, Gierusz LA, Iyer P, Lane FM, Graham JF, Goldmann W, Pinheiro TJT, Gill AC. Complex folding and misfolding effects of deer-specific amino acid substitutions in the β2-α2 loop of murine prion protein. Scientific Reports. 2015;5:1–14. doi: 10.1038/srep15528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Agashe VR, Udgaonkar JB. Thermodynamics of denaturation of barstar: evidence for cold denaturation and evaluation of the interaction with guanidine hydrochloride. Biochemistry. 1995;34:3286–3299. doi: 10.1021/bi00010a019. [DOI] [PubMed] [Google Scholar]
  3. Bertsch RA, Vaidehi N, Chan SI, Goddard WA. Kinetic steps for alpha-helix formation. Proteins: Structure, Function, and Genetics. 1998;33:343–357. doi: 10.1002/(SICI)1097-0134(19981115)33:3&#x0003c;343::AID-PROT4&#x0003e;3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  4. Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. The Journal of Biological Chemistry. 1992;267:16188–16199. [PubMed] [Google Scholar]
  5. Calamai M, Taddei N, Stefani M, Ramponi G, Chiti F. Relative influence of hydrophobicity and net charge in the aggregation of two homologous proteins. Biochemistry. 2003;42:15078–15083. doi: 10.1021/bi030135s. [DOI] [PubMed] [Google Scholar]
  6. Cereghetti GM, Schweiger A, Glockshuber R, Van Doorslaer S. Stability and cu(II) binding of prion protein variants related to inherited human prion diseases. Biophysical Journal. 2003;84:1985–1997. doi: 10.1016/S0006-3495(03)75007-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen J, Thirumalai D. Helices 2 and 3 are the initiation sites in the PrP(C) → PrP(SC) transition. Biochemistry. 2013;52:310–319. doi: 10.1021/bi3005472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chiti F, Calamai M, Taddei N, Stefani M, Ramponi G, Dobson CM. Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. PNAS. 2002a;99:16419–16426. doi: 10.1073/pnas.212527999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chiti F, Taddei N, Baroni F, Capanni C, Stefani M, Ramponi G, Dobson CM. Kinetic partitioning of protein folding and aggregation. Nature Structural Biology. 2002b;9:137–143. doi: 10.1038/nsb752. [DOI] [PubMed] [Google Scholar]
  10. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature. 2003;424:805–808. doi: 10.1038/nature01891. [DOI] [PubMed] [Google Scholar]
  11. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry. 2006;75:333–366. doi: 10.1146/annurev.biochem.75.101304.123901. [DOI] [PubMed] [Google Scholar]
  12. Cobb NJ, Sönnichsen FD, McHaourab H, Surewicz WK. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure. PNAS. 2007;104:18946–18951. doi: 10.1073/pnas.0706522104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Bertoncini CW, Wood NW, Knowles TP, Dobson CM, Klenerman D. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell. 2012;149:1048–1059. doi: 10.1016/j.cell.2012.03.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. DeMarco ML, Daggett V. From conversion to aggregation: protofibril formation of the prion protein. PNAS. 2004;101:2293–2298. doi: 10.1073/pnas.0307178101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Diaz-Espinoza R, Soto C. High-resolution structure of infectious prion protein: the final frontier. Nature Structural & Molecular Biology. 2012;19:370–377. doi: 10.1038/nsmb.2266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dima RI, Thirumalai D. Exploring the propensities of helices in PrP(C) to form beta sheet using NMR structures and sequence alignments. Biophysical Journal. 2002;83:1268–1280. doi: 10.1016/S0006-3495(02)73899-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ding F, Borreguero JM, Buldyrey SV, Stanley HE, Dokholyan NV. Mechanism for the alpha-helix to beta-hairpin transition. Proteins: Structure, Function, and Genetics. 2003;53:220–228. doi: 10.1002/prot.10468. [DOI] [PubMed] [Google Scholar]
  18. Dobson CM. Protein folding and misfolding. Nature. 2003;426:884–890. doi: 10.1038/nature02261. [DOI] [PubMed] [Google Scholar]
  19. Duim WC, Jiang Y, Shen K, Frydman J, Moerner WE. Super-resolution fluorescence of huntingtin reveals growth of globular species into short fibers and coexistence of distinct aggregates. ACS Chemical Biology. 2014;9:2767–2778. doi: 10.1021/cb500335w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Eghiaian F, Daubenfeld T, Quenet Y, van Audenhaege M, Bouin AP, van der Rest G, Grosclaude J, Rezaei H. Diversity in prion protein oligomerization pathways results from domain expansion as revealed by hydrogen/deuterium exchange and disulfide linkage. PNAS. 2007;104:7414–7419. doi: 10.1073/pnas.0607745104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gilch S, Wopfner F, Renner-Müller I, Kremmer E, Bauer C, Wolf E, Brem G, Groschup MH, Schätzl HM. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. Journal of Biological Chemistry. 2003;278:18524–18531. doi: 10.1074/jbc.M210723200. [DOI] [PubMed] [Google Scholar]
  22. Gossert AD, Bonjour S, Lysek DA, Fiorito F, Wüthrich K. Prion protein NMR structures of elk and of mouse/elk hybrids. PNAS. 2005;102:646–650. doi: 10.1073/pnas.0409008102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. PNAS. 2004;101:8342–8347. doi: 10.1073/pnas.0402254101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hadži S, Ondračka A, Jerala R, Hafner-Bratkovič I. Pathological mutations H187R and E196K facilitate subdomain separation and prion protein conversion by destabilization of the native structure. The FASEB Journal. 2015;29:882–893. doi: 10.1096/fj.14-255646. [DOI] [PubMed] [Google Scholar]
  25. Hafner-Bratkovic I, Bester R, Pristovsek P, Gaedtke L, Veranic P, Gaspersic J, Mancek-Keber M, Avbelj M, Polymenidou M, Julius C, Aguzzi A, Vorberg I, Jerala R. Globular domain of the prion protein needs to be unlocked by domain swapping to support prion protein conversion. Journal of Biological Chemistry. 2011;286:12149–12156. doi: 10.1074/jbc.M110.213926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hart T, Hosszu LL, Trevitt CR, Jackson GS, Waltho JP, Collinge J, Clarke AR. Folding kinetics of the human prion protein probed by temperature jump. PNAS. 2009;106:5651–5656. doi: 10.1073/pnas.0811457106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hennecke J, Sillen A, Huber-Wunderlich M, Engelborghs Y, Glockshuber R. Quenching of tryptophan fluorescence by the active-site disulfide bridge in the DsbA protein from Escherichia coli. Biochemistry. 1997;36:6391–6400. doi: 10.1021/bi963017w. [DOI] [PubMed] [Google Scholar]
  28. Hosszu LL, Tattum MH, Jones S, Trevitt CR, Wells MA, Waltho JP, Collinge J, Jackson GS, Clarke AR. The H187R mutation of the human prion protein induces conversion of recombinant prion protein to the PrP(Sc)-like form. Biochemistry. 2010;49:8729–8738. doi: 10.1021/bi100572j. [DOI] [PubMed] [Google Scholar]
  29. Jain S, Udgaonkar JB. Evidence for stepwise formation of amyloid fibrils by the mouse prion protein. Journal of Molecular Biology. 2008;382:1228–1241. doi: 10.1016/j.jmb.2008.07.052. [DOI] [PubMed] [Google Scholar]
  30. Jain S, Udgaonkar JB. Salt-induced modulation of the pathway of amyloid fibril formation by the mouse prion protein. Biochemistry. 2010;49:7615–7624. doi: 10.1021/bi100745j. [DOI] [PubMed] [Google Scholar]
  31. Jain S, Udgaonkar JB. Defining the pathway of worm-like amyloid fibril formation by the mouse prion protein by delineation of the productive and unproductive oligomerization reactions. Biochemistry. 2011;50:1153–1161. doi: 10.1021/bi101757x. [DOI] [PubMed] [Google Scholar]
  32. Jenkins DC, Sylvester ID, Pinheiro TJ. The elusive intermediate on the folding pathway of the prion protein. FEBS Journal. 2008;275:1323–1335. doi: 10.1111/j.1742-4658.2008.06293.x. [DOI] [PubMed] [Google Scholar]
  33. Jha SK, Udgaonkar JB. Direct evidence for a dry molten globule intermediate during the unfolding of a small protein. PNAS. 2009;106:12289–12294. doi: 10.1073/pnas.0905744106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kamatari YO, Hayano Y, Yamaguchi K, Hosokawa-Muto J, Kuwata K. Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones. Protein Science. 2013;22:22–34. doi: 10.1002/pro.2180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Khan MQ, Sweeting B, Mulligan VK, Arslan PE, Cashman NR, Pai EF, Chakrabartty A, Khipple V, Eli P, Cashman NR, Khan MQ, Sweeting B, Mulligan VK, Arslan PE, Cashman NR, Pai EF, Chakrabartty A, Khan MQQ, Sweeting B, Mulligan VK, Arslan PE, Cashman NR, Pai EF, Chakrabartty A. Prion disease susceptibility is affected by beta-structure folding propensity and local side-chain interactions in PrP. PNAS. 2010;107:19808–19813. doi: 10.1073/pnas.1005267107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Analytical Biochemistry. 1996;237:260–273. doi: 10.1006/abio.1996.0238. [DOI] [PubMed] [Google Scholar]
  37. Lakowicz JR. Principles of Fluorescence Spectroscopy. 3rd ed. New York: Springer-Verlag; 2006. [DOI] [Google Scholar]
  38. Lakshmikanth GS, Sridevi K, Krishnamoorthy G, Udgaonkar JB. Structure is lost incrementally during the unfolding of barstar. Nature Structural Biology. 2001;8:799–804. doi: 10.1038/nsb0901-799. [DOI] [PubMed] [Google Scholar]
  39. Larda ST, Simonetti K, Al-Abdul-Wahid MS, Sharpe S, Prosser RS. Dynamic equilibria between monomeric and oligomeric misfolded states of the mammalian prion protein measured by 19F NMR. Journal of the American Chemical Society. 2013;135:10533–10541. doi: 10.1021/ja404584s. [DOI] [PubMed] [Google Scholar]
  40. Lillo MP, Szpikowska BK, Mas MT, Sutin JD, Beechem JM. Real-time measurement of multiple intramolecular distances during protein folding reactions: a multisite stopped-flow fluorescence energy-transfer study of yeast phosphoglycerate kinase. Biochemistry. 1997;36:11273–11281. doi: 10.1021/bi970789z. [DOI] [PubMed] [Google Scholar]
  41. Lin Z, Puchalla J, Shoup D, Rye HS. Repetitive protein unfolding by the trans ring of the GroEL-GroES chaperonin complex stimulates folding. Journal of Biological Chemistry. 2013;288:30944–30955. doi: 10.1074/jbc.M113.480178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lin MM, Shorokhov D, Zewail AH. Dominance of misfolded intermediates in the dynamics of α-helix folding. PNAS. 2014;111:14424–14429. doi: 10.1073/pnas.1416300111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Margittai M, Langen R. Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Quarterly Reviews of Biophysics. 2008;41:265–297. doi: 10.1017/S0033583508004733. [DOI] [PubMed] [Google Scholar]
  44. Moulick R, Das R, Udgaonkar JB. Partially unfolded forms of the prion protein populated under Misfolding-promoting conditions. Journal of Biological Chemistry. 2015;290:25227–25240. doi: 10.1074/jbc.M115.677575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Orte A, Birkett NR, Clarke RW, Devlin GL, Dobson CM, Klenerman D. Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. PNAS. 2008;105:14424–14429. doi: 10.1073/pnas.0803086105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. PNAS. 1993;90:10962–10966. doi: 10.1073/pnas.90.23.10962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Pinotsi D, Buell AK, Galvagnion C, Dobson CM, Kaminski Schierle GS, Kaminski CF. Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy. Nano Letters. 2014;14:339–345. doi: 10.1021/nl4041093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Qin Z, Buehler MJ. Molecular dynamics simulation of the α-helix to β-sheet transition in coiled protein filaments: evidence for a critical filament length scale. Physical Review Letters. 2010;104:198304. doi: 10.1103/PhysRevLett.104.198304. [DOI] [PubMed] [Google Scholar]
  49. Rezaei H, Eghiaian F, Perez J, Doublet B, Choiset Y, Haertle T, Grosclaude J. Sequential generation of two structurally distinct ovine prion protein soluble oligomers displaying different biochemical reactivities. Journal of Molecular Biology. 2005;347:665–679. doi: 10.1016/j.jmb.2005.01.043. [DOI] [PubMed] [Google Scholar]
  50. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wüthrich K. NMR structure of the mouse prion protein domain PrP(121-231) Nature. 1996;382:180–182. doi: 10.1038/382180a0. [DOI] [PubMed] [Google Scholar]
  51. Sabareesan AT, Udgaonkar JB. Pathogenic mutations within the disordered palindromic region of the prion protein induce structure therein and accelerate the formation of misfolded oligomers. Journal of Molecular Biology. 2016;428:3935–3947. doi: 10.1016/j.jmb.2016.08.015. [DOI] [PubMed] [Google Scholar]
  52. Sabareesan AT, Udgaonkar JB. The G126V mutation in the mouse prion protein hinders Nucleation-Dependent fibril formation by slowing initial fibril growth and by increasing the critical concentration. Biochemistry. 2017;56:5931–5942. doi: 10.1021/acs.biochem.7b00894. [DOI] [PubMed] [Google Scholar]
  53. Sengupta I, Bhate SH, Das R, Udgaonkar JB. Salt-Mediated oligomerization of the mouse prion protein monitored by Real-Time NMR. Journal of Molecular Biology. 2017;429:1852–1872. doi: 10.1016/j.jmb.2017.05.006. [DOI] [PubMed] [Google Scholar]
  54. Sengupta I, Udgaonkar JB. Expression and purification of single cysteine-containing mutant variants of the mouse prion protein by oxidative refolding. Protein Expression and Purification. 2017;140:1–7. doi: 10.1016/j.pep.2017.07.014. [DOI] [PubMed] [Google Scholar]
  55. Shammas SL, Garcia GA, Kumar S, Kjaergaard M, Horrocks MH, Shivji N, Mandelkow E, Knowles TPJ, Mandelkow E, Klenerman D. A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nature Communications. 2015;6:1–10. doi: 10.1038/ncomms8025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B. The most infectious prion protein particles. Nature. 2005;437:257–261. doi: 10.1038/nature03989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Singh J, Sabareesan AT, Mathew MK, Udgaonkar JB. Development of the structural core and of conformational heterogeneity during the conversion of oligomers of the mouse prion protein to worm-like amyloid fibrils. Journal of Molecular Biology. 2012;423:217–231. doi: 10.1016/j.jmb.2012.06.040. [DOI] [PubMed] [Google Scholar]
  58. Singh J, Kumar H, Sabareesan AT, Udgaonkar JB. Rational stabilization of helix 2 of the prion protein prevents its misfolding and oligomerization. Journal of the American Chemical Society. 2014;136:16704–16707. doi: 10.1021/ja510964t. [DOI] [PubMed] [Google Scholar]
  59. Singh J, Udgaonkar JB. Dissection of conformational conversion events during prion amyloid fibril formation using hydrogen exchange and mass spectrometry. Journal of Molecular Biology. 2013;425:3510–3521. doi: 10.1016/j.jmb.2013.06.009. [DOI] [PubMed] [Google Scholar]
  60. Singh J, Udgaonkar JB. Structural effects of multiple pathogenic mutations suggest a model for the initiation of misfolding of the prion protein. Angewandte Chemie International Edition. 2015a;54:7529–7533. doi: 10.1002/anie.201501011. [DOI] [PubMed] [Google Scholar]
  61. Singh J, Udgaonkar JB. Molecular mechanism of the misfolding and oligomerization of the prion protein: current understanding and its implications. Biochemistry. 2015b;54:4431–4442. doi: 10.1021/acs.biochem.5b00605. [DOI] [PubMed] [Google Scholar]
  62. Singh J, Udgaonkar JB. Unraveling the molecular mechanism of pH-Induced misfolding and oligomerization of the prion protein. Journal of Molecular Biology. 2016a;428:1345–1355. doi: 10.1016/j.jmb.2016.01.030. [DOI] [PubMed] [Google Scholar]
  63. Singh J, Udgaonkar JB. The pathogenic mutation T182A converts the prion protein into a molten Globule-like conformation whose misfolding to oligomers but not to fibrils is drastically accelerated. Biochemistry. 2016b;55:459–469. doi: 10.1021/acs.biochem.5b01266. [DOI] [PubMed] [Google Scholar]
  64. Toyama BH, Weissman JS. Amyloid structure: conformational diversity and consequences. Annual Review of Biochemistry. 2011;80:557–585. doi: 10.1146/annurev-biochem-090908-120656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Tycko R, Savtchenko R, Ostapchenko VG, Makarava N, Baskakov IV. The α-helical C-terminal domain of full-length recombinant PrP converts to an in-register parallel β-sheet structure in PrP fibrils: evidence from solid state nuclear magnetic resonance. Biochemistry. 2010;49:9488–9497. doi: 10.1021/bi1013134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Yang C, Lo WL, Kuo YH, Sang JC, Lee CY, Chiang YW, Chen RP. Revealing structural changes of prion protein during conversion from α-helical monomer to β-oligomers by means of ESR and nanochannel encapsulation. ACS Chemical Biology. 2015;10:493–501. doi: 10.1021/cb500765e. [DOI] [PubMed] [Google Scholar]
  67. Yang J, Dear AJ, Michaels TCT, Dobson CM, Knowles TPJ, Wu S, Perrett S. Direct observation of oligomerization by single molecule fluorescence reveals a multistep aggregation mechanism for the yeast prion protein Ure2. Journal of the American Chemical Society. 2018;140:2493–2503. doi: 10.1021/jacs.7b10439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Yu H, Gupta AN, Liu X, Neupane K, Brigley AM, Sosova I, Woodside MT. Energy landscape analysis of native folding of the prion protein yields the diffusion constant, transition path time, and rates. PNAS. 2012;109:14452–14457. doi: 10.1073/pnas.1206190109. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision letter

Editor: Andreas Martin1

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article "Monitoring site-specific conformational changes in real-time reveals the misfolding mechanism of the prion protein" for consideration by eLife. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by John Kuriyan as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In the present manuscript, Sengupta and Udgaonkar use FRET-based measurements to investigate conformational changes occurring in the α2-α3 and β-1-α1-β2 subdomains of the mouse prion protein (moPrP) after its incorporation into oligomers at low pH. Based on differential changes in FRET between Trp residues (W144 in α1 or W197 in the α2-α3 linker) and TNB attached to engineered Cys in 4 positions around those subdomains, the authors propose a model for moPrP misfolding in which the α2-α3 segment initially compacts, before separating from the β1-α1-β2 subdomain, followed by α1 unfolding and transition of the α2-α3 segment into extended non-native β sheets.

Revealing the mechanism by which PrP converts into a misfolded isoform is difficult and complex, yet very important, as PrP is the archetype for disease-related propagated misfolding. In contrast to previous studies that mostly analyzed the global aggregation process, the presented FRET-based experiments allow the investigation of sub-steps and conformational transitions in individual domains of PrP. Performing the measurements at low pH is physiologically relevant based on the hypothesis that misfolding in the endosome plays an important role in pathogenesis and/or propagation.

Essential revisions:

In their revised full submission, the authors responded in detail to initial criticism regarding potential changes in Foerster radius upon oligomerization and the artificially fast misfolding behavior of TNB-labeled variant. While the concerns about changes in Foerster radius, quantum yield or kappa square of TNB have been addressed to full satisfaction, there remain major questions about the misfolding kinetics of the TNB- or DANS-labeled mutants. All reviewers agreed that these significant technical concerns need to be addressed prior to further consideration of this manuscript for eLife.

1) There are major concerns regarding to what extent the mutations and labels are responsible for the observed FRET behavior, and whether misfolding of WT PrP indeed follows the same rules. Whatever leads to faster oligomerization of labeled mutant PrP in isolation may also influence its oligomerization with WT PrP and thus have an effect on the measured FRET kinetics. It is quite intriguing that the rate of initial FRET increase (0.6 or 0.7 h-1) agrees very well with the accelerated misfolding/oligomerization kinetics of the isolated labeled mutants (0.61 – 0.78 h-1). The presented controls (CD and anisotropy) are dominated by the oligomerization behavior of the excess unlabeled "WT" PrP and are thus inept to probe whether the labeled mutant PrP dopant oligomerizes with WT PrP at an accelerated rate, followed by slower assembly of additional WT PrP.

CD measurements at 10 or 20% dopant revealed a 50% higher global rate of misfolding when fit to a single exponential, which may in fact indicate faster initial association of TNB-labeled monomers even with WT PrP. Clear double exponential behavior may be hard to detect, given the limited resolution (Figure 2B) and the expected low amplitude of a fast phase when using excess WT PrP.

These concerns about mutant and/or label effects on the FRET measurements are reinforced by the presented model, proposing that the fast conformational change, i.e. helix compaction, occurs at a rate of 0.6-0.7 h-1 only after oligomerization, yet all non-FRET readouts monitoring this oligomerization (e.g. anisotropy) show rates of ~ 0.1 h-1. How is that possible? Maybe the helix compaction and segment separation actually happen before oligomerization, in a spontaneous misfolding event that precedes assembly? This question relates to the essential debate about whether natively folded PrP fluctuates into a non-native structure before joining an aggregate, or whether it joins the aggregate and then re-configures.

To draw more solid conclusions, the authors need to use a more direct technique (e.g. FCS, SEC, DLS, AFM and/or inter-molecular-FRET) for assessing the formation kinetics as well as size changes with time for the PrP variants, especially the Trp-less PrP. How do the amount and size of oligomers change with time? Measuring the diffusion constant (and hence size) by FCS as a function of time may allow the authors to assess whether the FRET-labelled molecules are changing conformation before or after becoming incorporated into the oligomer.

Alternatively, the authors could consider applying some size fractionation method at different time-points to see whether labelled PrP has joined an oligomer before or after (or during) the fast structural change. This approach would have the advantage that different fractions could be characterized regarding their FRET efficiency, providing extra information about how the structure changes along with the growth of the oligomer.

2) Another issue lies in the fact that mutating multiple Trp residues likely affects protein structure, stability, and dynamics (i.e. activation barriers), which raises questions about the robustness of the conclusions and their applicability. For instance, the Trp-less PrP shows the slowest kinetics, which may indicate that it has some deficiency in conformational conversion and oligomerization. As a minimum, the authors should use an additional method to verify whether the oligomer of Trp-less PrP has similar properties and formation efficiency as the WT oligomers. Whether the fluorescence/FRET measurement using TrP-less PrP in the dopant experiment really represent the kinetics and mechanism of the WT normal PrP is unclear. This issue is intrinsic to the approach and cannot be resolved for the current study, but should be discussed accordingly. An important aspect to consider for the W197 mutants, however, is that the equivalent residue in human PrP, F198, is the site of a pathogenic mutation. F198S is associated with GSS syndrome, an inherited prion disease. That the W197 mutants of moPrP show faster misfolding and oligomerization in the present study could therefore be related to the fact that misfolding is particularly sensitive to this residue, even though an F to W mutation is much more conservative than the F to S mutation responsible for GSS syndrome.

3) There were initial concerns among the reviewers about the number of novel findings and the apparent overall advance provided by this work. Several previous studies had already concluded that the α2-α3 and β1-α1-β2 segments have to separate and α1 has to unfold prior to the β-conversion, leaving the potential compaction of the α2-α3 helices as the only major new result. However, these concern could be somewhat alleviated during the reviewers' discussions and a more in depth review of the literature, which revealed that previous work, for instance by Eghiaian et al. and Hafner-Bratkovic et al. using thermal denaturation or disulfide crosslinking, were less conclusive and more questionable regarding their relevance for the 'natural' misfolding process of PrP. In contrast, the present paper shows that domain separation occurs spontaneously in acidic conditions, which are endogenously found in endosomes. The authors should therefore better emphasize these advances of their study and in more detail put them into perspective to previous conclusions. Moreover, the somewhat turgid and disjointed writing of the paper does not do full justice to the assays and results. The manuscript is also strongly dominated by the setup of the system and various controls, whereas critical experiments and their discussion are proportionally slim, which should be improved in a revised version.

eLife. 2019 Jun 24;8:e44698. doi: 10.7554/eLife.44698.030

Author response


Essential revisions:

In their revised full submission, the authors responded in detail to initial criticism regarding potential changes in Foerster radius upon oligomerization and the artificially fast misfolding behavior of TNB-labeled variant. While the concerns about changes in Foerster radius, quantum yield or kappa square of TNB have been addressed to full satisfaction, there remain major questions about the misfolding kinetics of the TNB- or DANS-labeled mutants. All reviewers agreed that these significant technical concerns need to be addressed prior to further consideration of this manuscript for eLife.

1) There are major concerns regarding to what extent the mutations and labels are responsible for the observed FRET behavior, and whether misfolding of WT PrP indeed follows the same rules. Whatever leads to faster oligomerization of labeled mutant PrP in isolation may also influence its oligomerization with WT PrP and thus have an effect on the measured FRET kinetics. It is quite intriguing that the rate of initial FRET increase (0.6 or 0.7 h-1) agrees very well with the accelerated misfolding/oligomerization kinetics of the isolated labeled mutants (0.61 – 0.78 h-1). The presented controls (CD and anisotropy) are dominated by the oligomerization behavior of the excess unlabeled "WT" PrP and are thus inept to probe whether the labeled mutant PrP dopant oligomerizes with WT PrP at an accelerated rate, followed by slower assembly of additional WT PrP.

The reviewers have raised an interesting point: the observation that the rate of initial FRET increase for the 197-169 and 197-223 segments in the case of (2% dopant + 98% Trp-less protein) is the same as the rate of the CD-monitored rate for 100% dopant, could, in principle, suggest that the 2% dopant could be driving the 98% Trp-less protein to behave like 98% dopant during co-oligomerization. We think this is highly unlikely because the average oligomer size is about 50, and would therefore have only one dopant molecule. Nevertheless, it is important to demonstrate directly that 1 dopant molecule per 50-mer during co-aggregation is not responsible for the “intriguing” observation.

The similarity of rates alluded to, is only true when the dopant molecule is TNB–labelled. We have also carried out FRET experiments for monitoring the 197-169 and 197-223 segments, where instead, the dopant molecules are DANS-labelled. 100% DANS-labeled dopant molecules misfolded at a CD-monitored rate of ~2 h-1, which was about 2.5 fold faster than 100% TNB-labelled dopant molecules. Yet, the characteristic times (1/k) for the fast and slow phases of FRET change were comparable for (2% TNB-labelled dopant + 98% Trp-less protein) and (2% DANS-labelled dopant + 98% Trp-Less protein. If the fast change in FRET was indeed a consequence of the altered oligomerization kinetics of Trp-less protein co-aggregating with 2 mol% 197-223-TNB or 197-169-TNB, then it should have been ~2.5 fold faster for the corresponding DANS-labelled dopants. This is not the case. Hence, the fast FRET change is not an effect of the altered oligomerization kinetics of 98 μM Trp-less protein in the presence of 2 μM 197-169-TNB/DANS or 197-223-TNB/DANS, but is a consequence of the compaction of these sequence segments.

We discuss this in the sixth paragraph of the subsection “Site-specific conformational changes in moPrP monitored by intra-molecular FRET” where we state: “Moreover, even though the 100 μM DANS-labelled proteins by themselves misfolded with a characteristic time of ~0.5 h (Supplementary file 2), which was ~2.5 fold faster than the corresponding TNB-labelled proteins, the observed characteristic times of fluorescence and FRET-monitored changes, when the DANS-labelled proteins were used as dopant proteins, were in qualitative agreement with those of the corresponding TNB-labelled proteins (Figure 1—figure supplement 2, Figure 4—figure supplement 3 and Supplementary file 2). The lack of correlation between the timescales of misfolding of the labelled proteins by themselves, and timescales when the same proteins were used as dopant proteins, suggests that the fast changes in FRET efficiency are unlikely to be a consequence of altered co-oligomerization kinetics of 98 μM Trp-less moPrP when it co-oligomerizes with 2 μM dopant.”

We also point out that in our previous analysis of the rise and fall FRET kinetics seen for the 197-169 and 197-223 segments, we had assumed that the conformational changes were happening irreversibly. Our new SEC experiments, described below, have shown that two different oligomer populations (OS and OL) form reversibly from monomer M. We have re-analyzed our kinetic FRET data taking into account the SEC data, and we show that the two steps of FRET change seen for the 197-169 and 197-223 segments, occur during the formation of OL from M and of OS from OL. The analysis is described in the second paragraph of the subsection “Kinetic modelling of FRET and SEC data”, and also described below in response to a later point of the reviewers.

We also agree that the CD measurements are dominated by the oligomerization behavior of excess Trp-less moPrP. However, steady state tryptophan fluorescence anisotropy has no contribution from Trp-less moPrP, as it reports only on oligomers containing Trp. SS Trp fluorescence anisotropy therefore does not report on the oligomerization of Trp-less moPrP alone; it either reports solely on the oligomerization of 2 μM labeled moPrP, or the co-oligomerization of Trp-less and labeled moPrP. In the fourth paragraph of the subsection “Unlabelled and TNB-labelled mutant variants form misfolded co-oligomers with Trp-less moPrP with comparable kinetics”, we describe how our data clearly indicate that 2 μM labeled moPrP does not oligomerize independently when mixed with 98 μM Trp-less protein.

CD measurements at 10 or 20% dopant revealed a 50% higher global rate of misfolding when fit to a single exponential, which may in fact indicate faster initial association of TNB-labeled monomers even with WT PrP. Clear double exponential behavior may be hard to detect, given the limited resolution (Figure 2B) and the expected low amplitude of a fast phase when using excess WT PrP.

We agree that clear double exponential behavior may be hard to detect, given the limited resolution and the low amplitude of the fast phase. We have discussed this in the first paragraph of the subsection “Unlabelled and TNB-labelled mutant variants form misfolded co-oligomers with Trp-less moPrP with comparable kinetics” where we have stated: “TNB-labelled W197-C223 moPrP was chosen as the dopant as it misfolds nearly 10-fold faster by itself at 100% labelling density, compared to Trp-less moPrP (Supplementary file 2). […] It should be noted that although the observed kinetics appear to be described well by a single exponential equation, it is not possible to rule out the presence of two exponential components, with one component too small in amplitude to be detected.”

These concerns about mutant and/or label effects on the FRET measurements are reinforced by the presented model, proposing that the fast conformational change, i.e. helix compaction, occurs at a rate of 0.6-0.7 h-1 only AFTER oligomerization, yet all non-FRET readouts monitoring this oligomerization (e.g. anisotropy) show rates of ~ 0.1 h-1. How is that possible? Maybe the helix compaction and segment separation actually happen BEFORE oligomerization, in a spontaneous misfolding event that precedes assembly? This question relates to the essential debate about whether natively folded PrP fluctuates into a non-native structure before joining an aggregate, or whether it joins the aggregate and then re-configures.

We thank the reviewer for pointing out that the fast conformational change monitored by FRET may not be happening after the oligomer forms, as its rate constant is faster than the anisotropy monitored oligomerization rate constant.

On the other hand if the 0.6-0.7 h-1 FRET change were taking place in the monomer, before oligomerization, then it should be concentration independent, and would be observable even at the low concentration of 2 μM of labeled protein, in the absence of any Trp-less moPrP. However, we find that this conformational change is only observable at a total protein concentration of 100 μM, in the presence of 98 μM Trp-less moPrP.

We discuss this in the fourth paragraph of the subsection “Unlabelled and TNB-labelled mutant variants form misfolded co-oligomers with Trp-less moPrP with comparable kinetics” where we state: “The fluorescence spectra of the native monomers of the different unlabelled and labelled moPrP variants differed from those of the corresponding misfolded oligomers (Figure 1). […] These results also suggested that in the presence of 98 µM Trp-less moPrP, it was very unlikely that 2 µM dopant protein could misfold before oligomerization, and supported the results of the steady state Trp fluorescence anisotropy measurements which had indicated that the two proteins co-oligomerized.”

We describe, in our answer to the next point, how we have resolved the conundrum.

To draw more solid conclusions, the authors need to use a more direct technique (e.g. FCS, SEC, DLS, AFM and/or inter-molecular-FRET) for assessing the formation kinetics as well as size changes with time for the PrP variants, especially the Trp-less PrP. How do the amount and size of oligomers change with time? Measuring the diffusion constant (and hence size) by FCS as a function of time may allow the authors to assess whether the FRET-labelled molecules are changing conformation before or after becoming incorporated into the oligomer.

Alternatively, the authors could consider applying some size fractionation method at different time-points to see whether labelled PrP has joined an oligomer before or after (or during) the fast structural change. This approach would have the advantage that different fractions could be characterized regarding their FRET efficiency, providing extra information about how the structure changes along with the growth of the oligomer.

To resolve the matter, and to reach more solid conclusions, it was necessary to carry out new experiments, as suggested by the reviewers. Also importantly, it was important for us to remember our own results on oligomerization monitored by size exclusion chromatography SEC, published over the past decade.

In our earlier studies of wt moPrP, as well as of different mutant moPrP variants, we had shown that the oligomerization reaction leads to the formation of two oligomer populations, the large OL population and the smaller OS population. It was shown that the transitions between monomer (M) and OL and OS are reversible, and that during oligomerization the populations of the two oligomers change with respect to each other. Also importantly, OL could transform directly into OS.

We have now monitored oligomerization kinetics of 100 μM Trp-less moPrP using size-exclusion chromatography. In agreement with previous results with WT moPrP at pH 4, OL and OS were found to be populated. The populations of these oligomers changed, but their sizes (indicated by their elution volumes) remained fixed as oligomerization progressed. At the end of 60 h, we found the populations of monomer and oligomer (OS and OL)to be ~14% and ~86% respectively (by integrating the area under each curve). Again in agreement with previous results, M, OL and OS were seen to be interconverting. We tested sequential, parallel and triangular kinetic models by carrying out kinetic simulations and global fitting, and found that the sequential model M↔OL↔Os was able to account for both the size-exclusion and FRET data satisfactorily, with rate constants k1, k-1, k2 and k-2 of 0.09, 0.05, 0.09 and 0.03 h-1,respectively.

In view of these new results and our previous results, it is clear that our earlier analysis, where (i) we did not incorporate the formation of two oligomers and (ii) assumed the conversion between the monomer and oligomer to be irreversible, was obviously incorrect. The incorrect analysis also meant that the rate constants that we had obtained assuming irreversibility and only one oligomer population were erroneous.

To globally fit the FRET data, the FRET efficiency values for M, OL and OS were allowed to vary locally for each sequence-segment. Unfortunately, the FRET efficiency values of OL and OS could not be determined experimentally as the SEC column was not able to separate them adequately. We note that the global fitting routine predicted a high FRET efficiency value for OL and a low FRET efficiency value for OS for the 197-169 and 197-223 sequence segments.

The new data and analysis therefore resolve the question of when during oligomerization, do the fast FRET changes take place. They indicate that compaction of the erstwhile helical segment takes place along the course of formation of OL from M. The subsequent elongation of the erstwhile helical segments, takes place concomitant with the disassembly of OL to form OS.

We discuss this in the subsection “Oligomer formation monitored by size-exclusion chromatography” where we state: “To directly monitor the change in population and/or size of the oligomers, size-exclusion chromatography (SEC) was carried out. In agreement with previous results obtained with WT moPrP (Singh et al., 2014), Trp-less moPrP was found to form two populations of oligomers, the larger OL and the smaller OS, at pH 4 and 150 mM NaCl, As oligomerization progressed, the total amount of oligomers increased, but the sizes (as estimated from their elution volumes) remained fixed (Figure 3B). […] The poor resolution of the SEC column made it difficult to reliably estimate the relative amounts of OL and OS at equilibrium, but it appeared that, OS was populated to about a three-fold higher extent than was OL.”

And we also state in the subsection “Kinetic modelling of FRET and SEC data”: “Kinetic simulations and global fitting were carried out to test whether a parallel, sequential or triangular model best described the formation of OL and OS from M, taking into account both the SEC and FRET data. […] It is more appropriate to use the M↔OL ↔ OS mechanism, because it is a simpler kinetic model than the triangular model.”

2) Another issue lies in the fact that mutating multiple Trp residues likely affects protein structure, stability, and dynamics (i.e. activation barriers), which raises questions about the robustness of the conclusions and their applicability. For instance, the Trp-less PrP shows the slowest kinetics, which may indicate that it has some deficiency in conformational conversion and oligomerization. As a minimum, the authors should use an additional method to verify whether the oligomer of Trp-less PrP has similar properties and formation efficiency as the WT oligomers. Whether the fluorescence/FRET measurement using TrP-less PrP in the dopant experiment really represent the kinetics and mechanism of the WT normal PrP is unclear. This issue is intrinsic to the approach and cannot be resolved for the current study, but should be discussed accordingly.

We have now shown using size-exclusion chromatography, that Trp-less moPrP forms both oligomers OS and OL, to similar extents as compared to WT moPrP at pH 4 in the presence of 150 mM NaCl. We had characterized the oligomers of Trp-less moPrP (and the labelled and unlabeled mutant variant proteins) using DLS measurements and found them to be comparable to those of WT moPrP in an earlier paper. We have now included the DLS results for Trp-less and moPrP oligomers in this paper for better comparison. Furthermore, we have acknowledged the intrinsic caveat in this study in which Trp-less moPrP has been used as a pseudo WT moPrP analogue.

We discuss this in the Discussion as follows: “The presence of eight tryptophan residues in WT moPrP prevented its use in suppressing the intermolecular contributions to the FRET signal during oligomer formation. […] With this caveat in mind, the FRET measurements have allowed the delineation of the major structural changes that take place in the monomer, as it converts into soluble β-sheet rich oligomers at pH 4.”

An important aspect to consider for the W197 mutants, however, is that the equivalent residue in human PrP, F198, is the site of a pathogenic mutation. F198S is associated with GSS syndrome, an inherited prion disease. That the W197 mutants of moPrP show faster misfolding and oligomerization in the present study could therefore be related to the fact that misfolding is particularly sensitive to this residue, even though an F to W mutation is much more conservative than the F to S mutation responsible for GSS syndrome.

We note that for the mutant variants W197-C169 and W197-C223, only the former shows a ~2 fold increase in misfolding rates, whereas the latter remains unchanged, compared to WT moPrP (Supplementary file 2). Therefore, it cannot be concluded that the misfolding rate is faster in W197-C169 solely due to the F to W mutation. Instead, the faster misfolding rate for the W197-C169 mutant variant is possibly a result of the S169 to C169 mutation. This residue, located in the loop between β2 and α2 has been shown to be important in controlling the rigidity of the loop and affect the misfolding/aggregation propensity of the prion protein from different species.

We have discussed this as follows in the Supplementary Materials: “The unlabelled W197-C169 and W197-C223 mutant variants used here were not destabilized, supporting earlier observations that the F197W mutation does not perturb stability and/or unfolding/folding kinetics despite it being equivalent to residue F198 in human PrP, a site for the pathogenic mutation F198S associated with the inherited prion disease, the GSS syndrome (Jenkins et al., 2008). However, the W197-C169 mutant variant misfolded with slightly faster kinetics, compared to the WT moPrP, possibly due to its location in the loop between β2 and α2 (Agarwal et al., 2015; Gossert et al., 2005).”

3) There were initial concerns among the reviewers about the number of novel findings and the apparent overall advance provided by this work. Several previous studies had already concluded that the α2-α3 and β1-α1-β2 segments have to separate and α1 has to unfold prior to the β-conversion, leaving the potential compaction of the α2-α3 helices as the only major new result. However, these concern could be somewhat alleviated during the reviewers' discussions and a more in depth review of the literature, which revealed that previous work, for instance by Eghiaian et al. and Hafner-Bratkovic et al. using thermal denaturation or disulfide crosslinking, were less conclusive and more questionable regarding their relevance for the 'natural' misfolding process of PrP. In contrast, the present paper shows that domain separation occurs spontaneously in acidic conditions, which are endogenously found in endosomes. The authors should therefore better emphasize these advances of their study and in more detail put them into perspective to previous conclusions. Moreover, the somewhat turgid and disjointed writing of the paper does not do full justice to the assays and results. The manuscript is also strongly dominated by the setup of the system and various controls, whereas critical experiments and their discussion are proportionally slim, which should be improved in a revised version.

We thank the reviewers for pointing out that we need to better present the importance of our findings, especially in the context of earlier work.

We now state in the fifth paragraph of the Introduction: “While such equilibrium studies have suggested possible sequences of structural changes during oligomer formation (Singh and Udgaonkar, 2016b) there has been a dire need for kinetic studies that can directly delineate the structural mechanism of the misfolding which accompanies the oligomerization of the prion protein at low pH.”

We also now state in the fourth paragraph of the Discussion: “A qualitative comparison of the characteristic times of all structural changes monitored by FRET suggests that a compaction of the segments spanning the α2 and α3 helices is the fastest change (Table 1). […] The slowest change appears to be the elongation of sequence segments that had spanned α2 and α3; this is possibly due to their conversion into β-sheets and is also reported on by the global probe CD (Figure 6).”

In the seventh paragraph of the Discussion, we now describe our results in the context of previous hydrogen exchange-mass spectrometry measurements.

By carrying out SEC measurement of the oligomerization process, and by correlating the results of these measurements with the FRET measurements, we have now been able to describe a kinetic model for the formation of the two types of oligomers that are seen to form. Importantly we have been able to delineate the structural changes that occur during each of the two steps of oligomer formation. This is described in detail in the aforementioned paragraph.

In addition, we have now shortened our description of various controls and focussed more on the discussion of the critical results only.

We believe that the importance of our results is much better brought out in the revised manuscript.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Figure 2—source data 1. Raw data for Figure 2A–C.
    DOI: 10.7554/eLife.44698.006
    Figure 3—source data 1. Raw data for Figure 3.
    DOI: 10.7554/eLife.44698.009
    Figure 4—source data 1. Raw data for Figure 4A–J.
    DOI: 10.7554/eLife.44698.016
    Supplementary file 1. Parameters used for the estimation of FRET efficiency in monomeric moPrP mutant variants.
    elife-44698-supp1.docx (14.7KB, docx)
    DOI: 10.7554/eLife.44698.021
    Supplementary file 2. Thermodynamic parameters obtained from urea-induced equilibrium unfolding of different moPrP variants at pH 4 and their misfolding rate constants monitored by far-UV CD at 228 nm, for 100 µM protein.
    elife-44698-supp2.docx (14.7KB, docx)
    DOI: 10.7554/eLife.44698.022
    Supplementary file 3. Misfolding rate constants for Trp-less moPrP alone, 197–223-TNB alone and Trp-less moPrP doped with 1 mol %, 2 mol %, 10 mol % and 20 mol % of 197–223-TNB, monitored by far-UV CD at 228 nm.

    The total protein concentration in each case was 100 µM.

    elife-44698-supp3.docx (13.6KB, docx)
    DOI: 10.7554/eLife.44698.023
    Supplementary file 4. Apparent rate constant of co-oligomerization monitored by steady-state tryptophan fluorescence anisotropy at different dopant concentrations.
    elife-44698-supp4.docx (13.7KB, docx)
    DOI: 10.7554/eLife.44698.024
    Supplementary file 5. Rotational correlation times, amplitudes and fundamental anisotropy r(0) values derived from fitting the time-resolved anisotropy data of 1,5-IAEDANS-labelled W197-containing mutant variants in the monomeric and oligomeric forms.
    elife-44698-supp5.docx (13.9KB, docx)
    DOI: 10.7554/eLife.44698.025
    Transparent reporting form
    DOI: 10.7554/eLife.44698.026

    Data Availability Statement

    All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 3 and 4.


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES